{"status":"success","message":"The OTHER_DOC field for indicator 3-8-1, translated into all languages","data":{"ar":"","en":"<p><strong>URL: </strong><a href=\"https://www.who.int/health-topics/universal-health-coverage\">https://www.who.int/health-topics/universal-health-coverage</a></p>\n<p> </p>\n<p><strong>References: </strong><a href=\"https://www.who.int/publications/i/item/tracking-universal-health-coverage\">https://www.who.int/publications/i/item/tracking-universal-health-coverage</a> </p>\n<p><a href=\"http://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X(17)30472-2.pdf\" target=\"_blank\"><u>http://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X(17)30472-2.pdf</u></a> </p>\n<p><a href=\"https://www.who.int/health-topics/universal-health-coverage\">https://www.who.int/health-topics/universal-health-coverage</a></p>\n<p>For historical development of methods, see: </p>\n<p><a href=\"https://www.who.int/publications/i/item/9789241565264\">https://www.who.int/publications/i/item/9789241565264</a> </p>\n<p><a href=\"https://www.who.int/publications/i/item/monitoring-progress-towards-universal-health-coverage-at-country-and-global-levels-framework-measures-and-targets\">https://www.who.int/publications/i/item/monitoring-progress-towards-universal-health-coverage-at-country-and-global-levels-framework-measures-and-targets</a> </p>\n<p><a href=\"http://collections.plos.org/uhc2014\" target=\"_blank\"><u>http://collections.plos.org/uhc2014</u></a> </p>\n<p> </p>\n<p>Annex 1: Metadata for tracer indicators used to measure the coverage of essential health services for monitoring SDG indicator 3.8.1.</p>\n<p>Please send any comments or queries to: uhc_stats@who.int</p>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>Tracer area</p>\n      </td>\n      <td>\n        <p>Family planning</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Indicator definition</p>\n      </td>\n      <td>\n        <p>Percentage of women of reproductive age (15&#x2212;49 years) who are married or in-union who have their need for family planning satisfied with modern methods.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numerator</p>\n      </td>\n      <td>\n        <p>Number of women aged 15-49 who are married or in-union who are currently using, or whose partner is currently using a modern method of contraception </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Denominator</p>\n      </td>\n      <td>\n        <p>Number of women aged 15-49 who are married or in-union with a need for family planning </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Main data sources</p>\n      </td>\n      <td>\n        <p>Population-based health surveys</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Method of measurement</p>\n      </td>\n      <td>\n        <p>Household surveys include a series of questions to measure the modern contraceptive prevalence rate and need for family planning. The number of women with a need for family planning is defined as the sum of the number of women of reproductive age (15&#x2013;49 years) who are married or in a union and who are currently using, or whose sexual partner is currently using, at least one contraceptive method (modern or traditional), and the number of women of reproductive age with an unmet need for family planning. Unmet need for family planning is the proportion of women of reproductive age (15&#x2013;49 years) either married or in a consensual union, who are fecund and sexually active but who are not using any method of contraception (modern or traditional), and report not wanting any more children or wanting to delay the birth of their next child for at least two years. Included are:</p>\n        <ol>\n          <li>all pregnant women (married or in a consensual union) whose pregnancies were unwanted or mistimed at the time of conception;</li>\n          <li>all postpartum amenorrhoeic women (married or in consensual union) who are not using family planning and whose last birth was unwanted or mistimed;</li>\n          <li>all fecund women (married or in consensual union) who are neither pregnant nor postpartum amenorrhoeic, and who either do not want any more children (want to limit family size), or who wish to postpone the birth of a child for at least two years or do not know when or if they want another child (want to space births), but are not using any contraceptive method.</li>\n        </ol>\n        <p>Modern methods include female and male sterilization, the intra-uterine device (IUD), the implant, injectables, oral contraceptive pills, male and female condoms, vaginal barrier methods (including the diaphragm, cervical cap and spermicidal foam, jelly, cream and sponge), lactational amenorrhea method (LAM), emergency contraception and other modern methods not reported separately.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Method of estimation</p>\n      </td>\n      <td>\n        <p>The United Nations Population Division produces a systematic and comprehensive series of annual estimates and projections of the proportion of need for family planning among women of reproductive age (15-49) satisfied with modern methods. A Bayesian hierarchical model is applied to a comprehensive global dataset of a country-specific data to generate the estimates and projections. The model accounts for differences by data source, sample population, and survey questions. </p>\n        <p>See here for details: </p>\n        <p><a href=\"https://www.un.org/development/desa/pd/data/family-planning-indicators\">https://www.un.org/development/desa/pd/data/family-planning-indicators</a> </p>\n        <p>Data compilation of country-specific survey data in World Contraceptive Use: </p>\n        <p><a href=\"https://www.un.org/development/desa/pd/node/3285\">https://www.un.org/development/desa/pd/node/3285</a> </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>UHC-related notes</p>\n      </td>\n      <td></td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>Tracer area</p>\n      </td>\n      <td>\n        <p>Pregnancy care</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Indicator definition</p>\n      </td>\n      <td>\n        <p>Percentage of women aged 15-49 years with a live birth in a given time period who received antenatal care four or more times </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numerator</p>\n      </td>\n      <td>\n        <p>Number of women aged 15&#x2212;49 years with a live birth in a given time period who received antenatal care four or more times</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Denominator</p>\n      </td>\n      <td>\n        <p>Total number of women aged 15&#x2212;49 years with a live birth in the same period.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Main data sources</p>\n      </td>\n      <td>\n        <p>Household surveys and routine facility information systems.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Method of measurement</p>\n      </td>\n      <td>\n        <p>Data on four or more antenatal care visits is based on questions that ask if and how many times the health of the woman was checked during pregnancy. Household surveys that can generate this indicator include DHS, MICS, RHS and other surveys based on similar methodologies. Service/facility reporting systems can be used where the coverage is high, usually in higher income countries.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Method of estimation</p>\n      </td>\n      <td>\n        <p>WHO maintains a data base on coverage of antenatal care: <a href=\"http://apps.who.int/gho/data/node.main.ANTENATALCARECOVERAGE4\"><u>http://apps.who.int/gho/data/node.main.ANTENATALCARECOVERAGE4</u></a></p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>UHC-related notes</p>\n      </td>\n      <td>\n        <p>Ideally this indicator would be replaced with a more comprehensive measure of pregnancy care, for example the proportion of women who have a skilled provider attend the birth or an institutional delivery. A challenge in measuring skilled attendance at birth is determining which providers are &#x201C;skilled&#x201D;. </p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>Tracer area</p>\n      </td>\n      <td>\n        <p>Child immunization</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Indicator definition</p>\n      </td>\n      <td>\n        <p>Percentage of infants receiving three doses of diphtheria-tetanus-pertussis containing vaccine</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numerator</p>\n      </td>\n      <td>\n        <p>Children 1 year of age who have received three doses of diphtheria-tetanus-pertussis containing vaccine</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Denominator</p>\n      </td>\n      <td>\n        <p>All children 1 year of age</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Main data sources</p>\n      </td>\n      <td>\n        <p>Household surveys and facility information systems.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Method of measurement</p>\n      </td>\n      <td>\n        <p>For survey data, the vaccination status of children aged 12&#x2013;23 months is collected from child health cards or, if there is no card, from recall by the care-taker. For administrative data, the total number of doses administered to the target population is extracted.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Method of estimation</p>\n      </td>\n      <td>\n        <p>Together, WHO and UNICEF derive estimates of DTP3 coverage based on data officially reported to WHO and UNICEF by Member States, as well as data reported in the published and grey literature. They also consult with local experts - primarily national EPI managers and WHO regional office staff - for additional information regarding the performance of specific local immunization services. Based on the available data, consideration of potential biases, and contributions from local experts, WHO/UNICEF determine the most likely true level of immunization coverage. </p>\n        <p>For details, see here: </p>\n        <p> <a href=\"https://www.who.int/teams/immunization-vaccines-and-biologicals/immunization-analysis-and-insights/global-monitoring/immunization-coverage/who-unicef-estimates-of-national-immunization-coverage\">https://www.who.int/teams/immunization-vaccines-and-biologicals/immunization-analysis-and-insights/global-monitoring/immunization-coverage/who-unicef-estimates-of-national-immunization-coverage</a></p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>UHC-related notes</p>\n      </td>\n      <td>\n        <p>There is variability in national vaccine schedules across countries. Given this, one option for monitoring full child immunization is to monitor the fraction of children receiving vaccines included in their country&#x2019;s national schedule. A second option, which may be more comparable across countries and time, is to monitor DTP3 coverage as a proxy for full child immunization. Diphtheria-tetanus-pertussis containing vaccine often includes other vaccines, e.g., against Hepatitis B and Haemophilus influenza type B, and is a reasonable measure of the extent to which there is a robust vaccine delivery platform within a country. </p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>Tracer area</p>\n      </td>\n      <td>\n        <p>Child treatment </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Indicator definition</p>\n      </td>\n      <td>\n        <p>Percentage of children younger than 5 years with symptoms of acute respiratory infection (cough and fast or difficult breathing <strong>due to a problem in the chest</strong> <strong>and not due to a blocked nose only</strong>) in the 2 weeks preceding the survey for whom advice or treatment was sought from a health facility or provider</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numerator</p>\n      </td>\n      <td>\n        <p>Number of children younger than 5 years with symptoms of acute respiratory infection (cough and fast or difficult breathing <strong>due to a problem in the chest</strong> <strong>and not due to a blocked nose only</strong>) in the 2 weeks preceding the survey for whom advice or treatment was sought from a health facility or provider</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Denominator</p>\n      </td>\n      <td>\n        <p>Number of children younger than 5 years with symptoms of acute respiratory infection (cough and fast or difficult breathing <strong>due to a problem in the chest</strong> <strong>and not due to a blocked nose only</strong>) in the 2 weeks preceding the survey </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Main data sources</p>\n      </td>\n      <td>\n        <p>Household surveys</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Method of measurement</p>\n      </td>\n      <td>\n        <p>The indicator is captured by household surveys including DHS, MICS and other national population-based surveys and is intended for use in high under-5 mortality settings to monitor efforts to reduce mortality from acute respiratory infections (including pneumonia) which are a leading cause of death for children under the age of 5 years. The Child Health Accountability Tracking Technical Advisory Group (CHAT TAG), convened by WHO and UNICEF, has ratified this indicator and is working to standardize its use across household surveys.</p>\n        <p>WHO/UNICEF maintains a database of country-level observations from household surveys that can be accessed here: <a href=\"https://data.unicef.org/topic/child-health/pneumonia/\">https://data.unicef.org/topic/child-health/pneumonia/</a> </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Method of estimation</p>\n      </td>\n      <td>\n        <p>UNICEF and WHO maintain a data base on this indicator and work on ensuring that values presented are comparable, using the same indicator definition.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>UHC-related notes</p>\n      </td>\n      <td>\n        <p>This indicator is not typically measured in higher income countries with well-established health systems. </p>\n        <p>For countries without observed data, coverage was estimated from a regression that predicts coverage of care-seeking for symptoms of acute respiratory infection (on the logit scale), obtained from the WHO data base described above, as a function of the log of the estimated under-five all-causes mortality rate, which can be found here: <a href=\"https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates\">https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates</a></p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>Tracer area</p>\n      </td>\n      <td>\n        <p>Tuberculosis treatment</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Indicator definition</p>\n      </td>\n      <td>\n        <p>Percentage of incidence TB cases that are detected and treated in a given year</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numerator</p>\n      </td>\n      <td>\n        <p>Number of new and relapse cases detected and treated in a given year </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Denominator</p>\n      </td>\n      <td>\n        <p>Number of new and relapse cases in the same year</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Main data sources</p>\n      </td>\n      <td>\n        <p>Facility information systems, surveillance systems, population-based health surveys with TB diagnostic testing, TB register and related quarterly reporting system (or electronic TB registers)</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Method of measurement</p>\n      </td>\n      <td>\n        <p>This indicator requires two main inputs:</p>\n        <p>(1) The number of new and relapse TB cases diagnosed and treated in national TB control programmes and notified to WHO in a given year.</p>\n        <p>(2) The number of incident TB cases for the same year, typically estimated by WHO.</p>\n        <p>The final indicator = (1)/(2) </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Method of estimation</p>\n      </td>\n      <td>\n        <p>Estimates of TB incidence are produced through a consultative and analytical process led by WHO and are published annually. These estimates are based on annual case notifications, assessments of the quality and coverage of TB notification data, national surveys of the prevalence of TB disease and information from death (vital) registration systems. Estimates of incidence for each country are derived, using one or more of the following approaches depending on available data:</p>\n        <p>1. incidence = case notifications/estimated proportion of cases detected;</p>\n        <p>2. incidence = prevalence/duration of condition;</p>\n        <p>3. incidence = deaths/proportion of incident cases that die. </p>\n        <p>Dynamic and statistical models were introduced to produce estimates for 2020 and 2021 that account for the major disruptions to the provision of and access to TB diagnostic and treatment services that have occurred in the context of the coronavirus (COVID-19) pandemic.</p>\n        <p>These estimates of TB incidence are combined with country-reported data on the number of cases detected and treated, and the percentage of cases successfully treated, as described above.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>UHC-related notes</p>\n      </td>\n      <td>\n        <p>To compute the indicator using WHO estimates, one can access necessary files here: <a href=\"http://www.who.int/tb/country/data/download/en/\"><u>http://www.who.int/tb/country/data/download/en/</u></a>, and compute the indicator as = c_cdr </p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>Tracer area</p>\n      </td>\n      <td>\n        <p>HIV treatment</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Indicator definition</p>\n      </td>\n      <td>\n        <p>Percentage of adults and children living with HIV currently receiving antiretroviral therapy (ART)</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numerator</p>\n      </td>\n      <td>\n        <p>Number of adults and children who are currently receiving ART at the end of the reporting period</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Denominator</p>\n      </td>\n      <td>\n        <p>Number of adults and children living with HIV during the same period</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Main data sources</p>\n      </td>\n      <td>\n        <p>Facility reporting systems, sentinel surveillance sites, population-based surveys</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Method of measurement</p>\n      </td>\n      <td>\n        <p>Numerator: The numerator is generated by counting the number of adults and children who received ART at the end of the reporting period. Data can be collected from facility-based ART registers or drug supply management systems. These are then tallied and transferred to cross sectional monthly or quarterly reports which will then be aggregated for national totals. Patients receiving ART in the private sector and public sector should be included in the numerator.</p>\n        <p>Denominator: Data on the number of people with HIV infection may come from epidemic models and population-based surveys or, as is common in sub-Saharan Africa, surveillance systems based on antenatal care clinics.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Method of estimation</p>\n      </td>\n      <td>\n        <p>Estimates of antiretroviral treatment coverage among people living with HIV for 2000-2018 are derived as part of the 2019 UNAIDS&apos; estimation round. </p>\n        <p>To estimate the number of people living with HIV across time in high burden countries, UNAIDS in collaboration with countries use an epidemic model (Spectrum) that combines surveillance data on prevalence with the current number of patients receiving ART and assumptions about the natural history of HIV disease progression. </p>\n        <p>Since ART is now recommended for all individuals living with HIV, monitoring ART coverage is less complicated than before, when only those with a certain level of disease severity were eligible to receive ART.</p>\n        <p>Estimates of ART coverage can be found here: <a href=\"https://www.who.int/data/gho/data/indicators/indicator-details/GHO/estimated-antiretroviral-therapy-coverage-among-people-living-with-hiv-(-)\">https://www.who.int/data/gho/data/indicators/indicator-details/GHO/estimated-antiretroviral-therapy-coverage-among-people-living-with-hiv-(-)</a></p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>UHC-related notes</p>\n      </td>\n      <td>\n        <p>Comparable estimates of ART coverage in high income countries, in particular time trends, are not always available.</p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>Tracer area</p>\n      </td>\n      <td>\n        <p>Malaria prevention</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Indicator definition</p>\n      </td>\n      <td>\n        <p>Percentage of population in malaria-endemic areas who slept under an ITN the previous night.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numerator</p>\n      </td>\n      <td>\n        <p>Number of people in malaria-endemic areas who slept under an ITN.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Denominator</p>\n      </td>\n      <td>\n        <p>Total number of people in malaria endemic areas.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Main data sources</p>\n      </td>\n      <td>\n        <p>Data on household access and use of ITNs come from nationally representative household surveys such as Demographic and Health Surveys, Multiple Indicator Cluster Surveys, and Malaria Indicator Surveys. Data on the number of ITNs delivered by manufacturers to countries are compiled by Milliner Global Associates, and data on the number of ITNs distributed within countries are reported by National Malaria Control Programs.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Method of measurement</p>\n      </td>\n      <td>\n        <p>Many recent national surveys report the number of ITNs observed in each respondent household. Ownership rates can be converted to the proportion of people sleeping under an ITN using a linear relationship between access and use that has been derived from 62 surveys that collect information on both indicators. </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Method of estimation</p>\n      </td>\n      <td>\n        <p>Mathematical models can be used to combine data from household surveys on access and use with information on ITN deliveries from manufacturers and ITN distribution by national malaria programmes to produce annual estimates of ITN coverage. WHO uses this approach in collaboration with the Malaria Atlas Project. Methodological details can be found in pages 122-123 of the World Malaria Report 2021: <a href=\"https://www.who.int/publications/i/item/9789240040496\">https://www.who.int/publications/i/item/9789240040496</a>.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>UHC-related notes</p>\n      </td>\n      <td>\n        <p>WHO produces comparable ITN coverage estimates for 40 of the 47 malaria endemic countries or areas of sub-Saharan Africa. The islands of </p>\n        <p>Mayotte (for which no ITN delivery or distribution data </p>\n        <p>were available) and Cabo Verde (which does not distribute </p>\n        <p>ITNs) were excluded, as were the low transmission </p>\n        <p>countries of Eswatini, Namibia, Sao Tome and Principe, </p>\n        <p>and South Africa, for which ITNs comprise a small </p>\n        <p>proportion of vector control. Analyses were limited to </p>\n        <p>populations categorized by NMPs as being at risk. For other countries, ITN coverage is not included in the UHC service coverage index due to data limitations. </p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>Tracer area</p>\n      </td>\n      <td>\n        <p>Water, sanitation and hygiene</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Indicator definition</p>\n      </td>\n      <td>\n        <p>Percentage of population using at least basic sanitation services, that is, improved sanitation facilities that are not shared with other households</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numerator</p>\n      </td>\n      <td>\n        <p>Number of people using basic sanitation services as well as those using safely managed sanitation services. Improved sanitation facilities include flush/pour flush toilets connected to piped sewer systems, septic tanks or pit latrines; pit latrines with slabs (including ventilated pit latrines), and composting toilets</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Denominator</p>\n      </td>\n      <td>\n        <p>Total population</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Main data sources</p>\n      </td>\n      <td>\n        <p>Population-based household surveys and censuses</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Method of measurement</p>\n      </td>\n      <td>\n        <p>Data on improved sanitation facilities are routinely collected in household surveys and censuses. These data sources may also collect information on sharing of sanitation facilities are shared among two or more households, and on emptying of on-site sanitation facilities. Household-level responses, weighted by household size, are used to compute population coverage.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Method of estimation</p>\n      </td>\n      <td>\n        <p>The WHO/UNICEF Joint Monitoring Programme for Water Supply, Sanitation and Hygiene (JMP) is responsible for SDG reporting on drinking water, sanitation and hygiene (WASH) and has produced regular estimates of coverage of the population using at least basic sanitation services since 2000. The JMP assembles, reviews and assesses national data collected by statistics offices and other relevant institutions including sectoral authorities. Linear regression is used to provide estimates of the population using improved sanitation facilities, as well as the proportion practising open defecation. Regressions are also made to estimate the population using improved sanitation facilities connected to sewers and septic tanks; these are constrained to not exceed the estimates for total improved facilities. The proportion of the population sharing sewered and non-sewered sanitation facilities is estimated by making a linear regression on all available data on sharing from household surveys and censuses. Basic sanitation services are calculated by multiplying the proportion of the population using improved sanitation facilities by the proportion of improved sanitation facilities which are not shared among two or more households. Separate estimates are made for urban and rural areas, and national estimates are generated as weighted averages of the two, using population data from the most recent report of the United Nations Population Division. The most recent household survey or census available for most countries was typically conducted two to six years ago. The JMP extrapolates regressions for two years beyond the last available data point. Beyond this point the estimates remain unchanged for up to four years unless coverage is below 0.5 per cent or above 99.5 per cent, in which case the line is extended indefinitely. For more information see <a href=\"https://washdata.org/monitoring/methods/estimation-methods\">https://washdata.org/monitoring/methods/estimation-methods</a></p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>UHC-related notes</p>\n      </td>\n      <td>\n        <p>The SDG global indicator of &#x201C;proportion of population using safely managed sanitation services&#x201D; (SDG 6.2.1a) is an expanded version of the MDG indicator, which additionally considers safe management of excreta along the entire sanitation chain, including treatment and disposal This indicator is not used for UHC monitoring due to lower data availability. </p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>Tracer area</p>\n      </td>\n      <td>\n        <p>Prevention of cardiovascular disease</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Indicator definition</p>\n      </td>\n      <td>\n        <p>Prevalence of treatment (taking medicine) for hypertension among adults aged 30-79 years with hypertension (age-standardized estimate) (%)</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numerator</p>\n      </td>\n      <td>\n        <p>Number of adults aged 30-79 years who took medication for hypertension</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Denominator</p>\n      </td>\n      <td>\n        <p>Number of adults aged 30-79 years with hypertension (defined as having systolic blood pressure &#x2265; 140 mmHg, diastolic blood pressure &#x2265; 90 mmHg, or taking medication for hypertension)</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Main data sources</p>\n      </td>\n      <td>\n        <p>Population-based surveys and surveillance systems</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Method of measurement</p>\n      </td>\n      <td>\n        <p>Data sources recording measured blood pressure are used (self-reported data are excluded). If multiple blood pressure readings are taken per participant, the first reading is dropped and the remaining readings are averaged. Whether medication is taken for hypertension may be assessed using questions worded as variations of &#x201C;Are you currently taking any medicines, tablets, or pills for high blood pressure?&#x201D; or &#x201C;In the past 2 weeks, have you taken any drugs (medication) for raised blood pressure prescribed by a doctor or other health worker?&#x201D; In studies that gather information on prescribed medicines, survey information may be used to establish that the purpose of taking a blood pressure-lowering drug was specifically to treat hypertension.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Method of estimation</p>\n      </td>\n      <td>\n        <p>Full details of input and data methods are available at: NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. The Lancet S0140-6736(21)01330-1 (https://www.thelancet.com/article/S0140-6736(21)01330-1/fulltext). A total of 1,201 population-based studies that included measured blood pressure and data on blood pressure treatment in 104 million individuals aged 30&#x2013;79 years were used to estimate trends in hypertension and hypertension diagnosis, treatment and control from 1990 to 2019. Age-standardized estimates are produced by applying the crude estimates to the WHO Standard Population.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>UHC-related notes</p>\n      </td>\n      <td>\n        <p> </p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>Tracer area</p>\n      </td>\n      <td>\n        <p>Management of diabetes</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Indicator definition</p>\n      </td>\n      <td>\n        <p>Age-standardized mean fasting plasma glucose for adults aged 18 years and older</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Main data sources</p>\n      </td>\n      <td>\n        <p>Population-based surveys and surveillance systems</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Method of measurement</p>\n      </td>\n      <td>\n        <p>Fasting plasma glucose (FPG) levels are determined by taking a blood sample from participants who have fasted for at least 8 hours. Other related biomarkers, such as hemoglobin A1c (HbA1c), were used to help calculate estimates (see below).</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Method of estimation</p>\n      </td>\n      <td>\n        <p>For producing comparable national estimates, data observations based on mean FPG, oral glucose tolerance test (OGTT), HbA1c, or combinations therein, are all converted to mean FPG. A Bayesian hierarchical model is then fitted to these data to calculate age-sex-year-country specific prevalences, which accounts for national vs. subnational data sources, urban vs. rural data sources, and allows for variation in prevalence across age and sex. Age-standardized estimates are then produced by applying the crude estimates to the WHO Standard Population. Methodological details can be found here: <a href=\"https://www.who.int/diabetes/global-report/en/\"><u>https://www.who.int/diabetes/global-report/en/</u></a></p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>UHC-related notes</p>\n      </td>\n      <td>\n        <p>An individual&#x2019;s FPG may be low because of effective treatment with glucose-lowering medication, or because the individual is not diabetic as a result of health promotion activities or other factors such as genetics. Mean FPG is thus a proxy for both effective promotion of healthy diets and behaviors and effective treatment of diabetes. </p>\n        <p>The above estimates are done separately for men and women; for the UHC tracer indicator a simple average of values for men and women is computed. The indicator, which is a continuous measure (units of mmol/L), is converted to a scale of 0 to 100 using the minimum theoretical biological risk (5.1 mmol/L) and observed maximum across countries (7.41 mmol/L). </p>\n        <p>rescaled value = (7.41 - original value) / (7.41-5.1) * 100</p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>Tracer area</p>\n      </td>\n      <td>\n        <p>Tobacco control</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Indicator definition</p>\n      </td>\n      <td>\n        <p>Age-standardized percentage of the population aged 15 years and over who currently use any tobacco product (smoked and/or smokeless tobacco) on a daily or non-daily basis.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numerator</p>\n      </td>\n      <td>\n        <p>Estimated number of adults 15 years and older who currently use any tobacco product (smoked and/or smokeless tobacco) on a daily or non-daily basis</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Denominator</p>\n      </td>\n      <td>\n        <p>Total number of adults 15 years and older</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Main data sources</p>\n      </td>\n      <td>\n        <p>Household surveys</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Method of measurement</p>\n      </td>\n      <td>\n        <p>Tobacco products include cigarettes, pipes, cigars, cigarillos, waterpipes (hookah, shisha), bidis, kretek, heated tobacco products, and all forms of smokeless (oral and nasal) tobacco. Tobacco products exclude e-cigarettes (which do not contain tobacco), &#x201C;e-cigars&#x201D;, &#x201C;e-hookahs&#x201D;, JUUL and &#x201C;e-pipes&#x201D;.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Method of estimation</p>\n      </td>\n      <td>\n        <p>A statistical model based on a Bayesian negative binomial meta-regression is used to model prevalence of current tobacco use for each country, separately for men and women. A full description of the method is available as a peer-reviewed article in The Lancet, volume 385, No. 9972, p966&#x2013;976 (2015). Once the age-and-sex-specific prevalence rates from national surveys were compiled into a dataset, the model was fit to calculate trend estimates from the year 2000 to 2025. The model has two main components: (a) adjusting for missing indicators and age groups, and (b) generating an estimate of trends over time as well as the 95% credible interval around the estimate. Depending on the completeness/comprehensiveness of survey data from a particular country, the model at times makes use of data from other countries to fill information gaps. When a country has fewer than two nationally representative population-based surveys in different years, no attempt is made to fill data gaps and no estimates are calculated. To fill data gaps, information is &#x201C;borrowed&#x201D; from countries in the same UN subregion. The resulting trend lines are used to derive estimates for single years, so that a number can be reported even if the country did not run a survey in that year. In order to make the results comparable between countries, the prevalence rates are age-standardized to the WHO Standard Population. Estimates for countries with irregular surveys or many data gaps will have large uncertainty ranges, and such results should be interpreted with caution.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>UHC-related notes</p>\n      </td>\n      <td>\n        <p>Prevalence of tobacco non-use is computed as 1 minus the prevalence of tobacco use. The indicator is then rescaled based on a non-zero minimum to obtain finer resolution : rescaled tobacco non-use = (X-30)/(100-30)*100.</p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>Tracer area</p>\n      </td>\n      <td>\n        <p>Hospital access</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Indicator definition</p>\n      </td>\n      <td>\n        <p>Hospital beds per capita, relative to a maximum threshold of 18 per 10,000 population</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numerator</p>\n      </td>\n      <td>\n        <p>Number of hospital beds (should exclude labor and delivery beds)</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Denominator</p>\n      </td>\n      <td>\n        <p>Total population</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Main data sources</p>\n      </td>\n      <td>\n        <p>Administrative systems / Health facility reporting system</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Method of measurement</p>\n      </td>\n      <td>\n        <p>Country administrative systems are used to total the number of hospital beds, which are divided by the total estimated population, and multiplied by 10,000. </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Method of estimation</p>\n      </td>\n      <td>\n        <p>Using available data, the indicator is computed relative to a threshold value of 18 hospital beds per 10,000 population. This threshold is below the observed OECD high income country minimum (since year 2000) of 20 per 10,000 (OECD Health Statistics database, 2015 edition) and tends to correspond to an inpatient hospital admission rate of around 5 per 100 per year. This indicator is designed to capture low levels of hospital capacity; the maximum threshold is used because very high hospital bed densities are not necessary an efficient use of resources. The indicator is computed as follows, using country data on hospital bed density (<em>x</em>), which results in values ranging from 0 to 100:</p>\n        <ul>\n          <li>Country with a hospital bed density <em>x</em> &lt; 18 per 10,000 per year, the indicator = <em>x</em> /18*100. </li>\n          <li>Country with a hospital bed density <em>x</em> &gt;= 18 per 10,000 per year, the indicator = 100.</li>\n        </ul>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>UHC-related notes</p>\n      </td>\n      <td>\n        <p>This indicator is used as proxy for the full coverage of inpatient care services. An alternative indicator could be hospital in-patient admission rate, relative to a maximum threshold. However, that indicator is currently not reported widely across regions, in particular the African Region. In countries where both hospital beds per capita and in-patient admission rates are available, they are highly correlated.</p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>Tracer area</p>\n      </td>\n      <td>\n        <p>Health workforce</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Indicator definition</p>\n      </td>\n      <td>\n        <p>Health professionals (physicians, psychiatrists, and surgeons) per capita, relative to maximum thresholds for each cadre</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numerator</p>\n      </td>\n      <td>\n        <p>Number of physicians, psychiatrists and surgeons</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Denominator</p>\n      </td>\n      <td>\n        <p>Total population</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Main data sources</p>\n      </td>\n      <td>\n        <p>National Health Workforce Accounts. This includes reported data from Member States based on national registry of health workers, ideally coupled with regular assessment of completeness using census data, labour force surveys, professional association registers, or facility censuses.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Method of measurement</p>\n      </td>\n      <td>\n        <p>The classification of health workers is based on criteria for vocational education and training, regulation of health professions, and activities and tasks of jobs, i.e., a framework for categorizing key workforce variables according to shared characteristics. The WHO framework largely draws on the latest revisions to the internationally standardized classification systems of the International Labour Organization (International Standard Classification of Occupations), United Nations Educational, Scientific and Cultural Organization (International Standard Classification of Education), and the United Nations Statistics Division (International Standard Industrial Classification of All Economic Activities). Methodological details can be found here: <a href=\"https://www.who.int/activities/improving-health-workforce-data-and-evidence\">https://www.who.int/activities/improving-health-workforce-data-and-evidence</a></p>\n        <p>Health workforce data can be accessed on the NHWA data portal: <a href=\"https://apps.who.int/nhwaportal/\">https://apps.who.int/nhwaportal/</a></p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Method of estimation</p>\n      </td>\n      <td>\n        <p>Using available data, the indicator is computed by first rescaling, separately, health worker density ratios for each of the three cadres (physicians, psychiatrists and surgeons) relative to the minimum observed values across OECD countries since 2000 (OECD Health Statistics database, 2015 edition), which are as follows: physicians = 0.9 per 1000, psychiatrists = 1 per 100,000, and surgeons = 14 per 100,000. This rescaling is done in the same way as that for the hospital bed density indicator described above, resulting in indicator values that range from 0 to 100 for each of the three cadres. For example, using country data on physicians per 1000 population (<em>x</em>), the cadre-specific indicator would be computed as:</p>\n        <ul>\n          <li>Country with <em>x</em> &lt; 0.9 per 1000 per year, the cadre-specific indicator = <em>x</em> /0.9*100. </li>\n          <li>Country with <em>x</em> &gt;= 0.9 per 1000 per year, the cadre-specific indicator = 100.</li>\n        </ul>\n        <p>As a final step, the geometric mean of the three cadre-specific indicator values is computed to obtain the final indicator of health workforce density.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>UHC-related notes</p>\n      </td>\n      <td>\n        <p>Due to major challenges measuring coverage in all health areas, which leaves major gaps for important areas such as routine medical exams, treatment for mental illnesses, emergency care and surgical procedure, proxies are used. Physician, psychiatrist and surgeon densities are used as proxies for the full coverage of outpatient care, mental health care and emergency/surgical care services, respectively. It should be noted that those measures are difficult to interpret because the optimal level for those indicators is unknown and they do not relate to a specific need for services. Despite this fact, low levels for these indicators are indicative of poor access to and use of essential health services.</p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>Tracer area</p>\n      </td>\n      <td>\n        <p>Health security</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Indicator definition</p>\n      </td>\n      <td>\n        <p>International Health Regulations (IHR) core capacity index, which is the average percentage of attributes of all core capacities that have been attained at a specific point in time. </p>\n        <p>The second edition SPAR tool has been expanded from 13 to 15 capacities. The 15 core capacities are (1) Policy, legal and normative instruments to implement IHR; (2) IHR Coordination and National Focal Point Functions; (3) Financing; (4) Laboratory; (5) Surveillance; (6) Human resources; (7) Health emergency management (8) Health Service Provision; (9) Infection Prevention and Control; (10) Risk communication and community engagement; (11) Points of entry and border health; (12) Zoonotic diseases; (13) Food safety; (14) Chemical events; (15) Radiation emergencies. </p>\n        <p>The 13 core capacities of the first edition of the IHR State Parties Annual Assessment and Reporting Tool are (1) Legislation and financing; (2) IHR Coordination and National Focal Point Functions; (3) Zoonotic events and the Human-Animal Health Interface; (4) Food safety; (5) Laboratory; (6) Surveillance; (7) Human resources; (8) National Health Emergency Framework; (9) Health Service Provision; (10) Risk communication; (11) Points of entry; (12) Chemical events; (13) Radiation emergencies. </p>\n        <p>Both SPAR questionnaires (1st and 2nd editions) use a five-level scoring with indicators based on five cumulative levels to measure the implementation status for each capacity. For each indicator, the reporting State Party is asked to select which of the five levels best describes the State Party&apos;s current status. To move to the next level, all capacities described in previous levels should be in place for each indicator.</p>\n        <p>For the years 2010 to 2017, Member States used the IHR monitoring questionnaire. The questionnaire is divided into thirteen sections, one for each of the eight core capacities, PoE and four hazards. Individual questions are grouped by components and indicators in the questionnaires. States Parties can provide additional information on the questions in the comment boxes. Responses to the questions include marking one appropriate value (Yes, No, or Not Known) or the appropriate percentages. For statistical purposes, the &quot;Not Known&quot; value will be computed as a &quot;No&quot; value. The IHR monitoring questionnaire includes the following: IHR01. National legislation, policy and financing; IHR02. Coordination and National Focal Point communications; IHR03. Surveillance; IHR04. Response; IHR05. Preparedness; IHR06. Risk communication; IHR07. Human resources; IHR08. Laboratory; IHR09. Points of entry; IHR10. Zoonotic events; IHR11. Food safety; IHR12. Chemical events; IHR13. Radio nuclear emergencies.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numerator</p>\n      </td>\n      <td>\n        <p>Number of attributes attained</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Denominator</p>\n      </td>\n      <td>\n        <p>Total number of attributes</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Main data sources</p>\n      </td>\n      <td>\n        <p>Key informant survey</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Method of measurement</p>\n      </td>\n      <td>\n        <p>Key informants report on attainment of a set of attributes for each of the core capacities using a standard WHO instrument. This instrument is based on a self-assessment and self-reporting by the State Party. There are three datasets based on the different tools to collect data for SPAR. For the period 2010 to 2017, the questionnaire, known as the IHR monitoring questionnaire, is divided into thirteen sections, one for each of the eight core capacities, PoE and four hazards and information on the status of implementation for each capacity. The IHR monitoring questionnaire ( 2010 to 2017) was replaced by the IHR State Parties Self-Assessment Tool &#x2013; SPAR, published in July 2018 also known as SPAR 1st edition. The States Parties used the questionnaire from the 2018 &#x2013; 2020 SPAR reporting cycle. The current questionnaire replaced the SPAR 1st edition and was used by the Member States for 2021. Under each capacity, the indicators were either retained, replaced or added. Historical trends based on the data for similar capacity titles may be taken with caution.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Method of estimation</p>\n      </td>\n      <td>\n        <p>The score of each indicator level is classified as a percentage of performance along the &#x201C;1 to 5&#x201D; scale. e.g. for a country selecting level 3 for indicator 2.1, the indicator level will be expressed as: 3/5*100=60% CAPACITY LEVEL The level of the capacity is expressed as the average of all indicators. e.g. for a country selecting level 3 for indicator 2.1 and level 4 for indicator 2.2. Indicator level for 2.1 will be expressed as: 3/5*100=60%, indicator level for 2.2 will be expressed as: 4/5*100=80% and capacity level for 2 will be expressed as: (60+80)/2=70%</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>UHC-related notes</p>\n      </td>\n      <td>\n        <p>Countries began reporting IHR core capacity attainment to WHO for the year 2010. The earliest available IHR score for each country is used for all years 2000-2009.</p>\n      </td>\n    </tr>\n  </tbody>\n</table>","es":"<h1>Referencias</h1>\n<h2><strong>URL: </strong></h2>\n<p><a href=\"http://www.who.int/healthinfo/universal_health_coverage/en/\">http://www.who.int/healthinfo/universal_health_coverage/en/</a></p>\n<h2><strong>Referencias: </strong></h2>\n<p><a href=\"http://www.who.int/healthinfo/universal_health_coverage/report/2017/en/\">http://www.who.int/healthinfo/universal_health_coverage/report/2017/en/</a></p>\n<p><a href=\"http://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X(17)30472-2.pdf\">http://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X(17)30472-2.pdf</a></p>\n<p><a href=\"http://www.who.int/healthinfo/universal_health_coverage/en/\">http://www.who.int/healthinfo/universal_health_coverage/en/</a></p>\n<p>Para la evolucin histrica de los mtodos, vase:</p>\n<p><a href=\"http://www.who.int/healthinfo/universal_health_coverage/UHC_WHS2016_TechnicalNote_May2016.pdf?ua=1\">http://www.who.int/healthinfo/universal_health_coverage/UHC_WHS2016_TechnicalNote_May2016.pdf?ua=1</a> (sustituido por este documento)</p>\n<p><a href=\"http://www.who.int/healthinfo/universal_health_coverage/report/2015/en/\">http://www.who.int/healthinfo/universal_health_coverage/report/2015/en/</a></p>\n<p><a href=\"http://www.who.int/healthinfo/universal_health_coverage/report/2014/en/\">http://www.who.int/healthinfo/universal_health_coverage/report/2014/en/</a></p>\n<p><a href=\"http://collections.plos.org/uhc2014\">http://collections.plos.org/uhc2014</a></p>\n<h1>Anexo 1: Metadatos de los indicadores trazadores utilizados para medir la cobertura de los servicios sanitarios esenciales para el seguimiento del indicador 3.8.1 de los ODS.</h1>\n<p>Por favor, enve cualquier comentario o consulta a: <a href=\"mailto:uhc_stats@who.int\">uhc_stats@who.int</a></p>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>rea del trazador</p>\n      </td>\n      <td>\n        <p>Planificacin familiar</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Definicin del indicador</p>\n      </td>\n      <td>\n        <p>Porcentaje de mujeres en edad reproductiva (15&#x2212;49 aos) casadas o en unin libre que tienen su necesidad de planificacin familiar satisfecha con mtodos modernos</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numerador</p>\n      </td>\n      <td>\n        <p>Nmero de mujeres de 15 a 49 aos casadas o unidas que utilizan mtodos modernos</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Denominador</p>\n      </td>\n      <td>\n        <p>Nmero total de mujeres de 15 a 49 aos casadas o unidas que necesitan planificacin familiar</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Principales fuentes de datos</p>\n      </td>\n      <td>\n        <p>Encuestas de salud basadas en la poblacin</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mtodo de medicin</p>\n      </td>\n      <td>\n        <p>Las encuestas de hogares incluyen una serie de preguntas para medir la tasa de prevalencia de anticonceptivos modernos y la demanda de planificacin familiar. La demanda total de planificacin familiar se define como la suma del nmero de mujeres en edad reproductiva (15&#x2013;49 aos) que estn casadas o en pareja y que actualmente utilizan, o cuya pareja sexual utiliza actualmente, al menos un mtodo anticonceptivo, y la necesidad insatisfecha de planificacin familiar. La necesidad insatisfecha de planificacin familiar es la proporcin de mujeres en edad reproductiva (15&#x2013;49 aos) casadas o en una unin consensuada, que son fecundas y sexualmente activas pero que no utilizan ningn mtodo anticonceptivo (moderno o tradicional), y que declaran no querer tener ms hijos o querer retrasar el nacimiento de su siguiente hijo durante al menos dos aos. Se incluyen:</p>\n        <p>todas las mujeres embarazadas (casadas o en una unin consensuada) cuyos embarazos fueron no deseados o inoportunos en el momento de la concepcin;</p>\n        <p>todas las mujeres amenorreicas posparto (casadas o en unin consensuada) que no utilizan planificacin familiar y cuyo ltimo parto fue no deseado o inoportuno;</p>\n        <p>Todas las mujeres fecundas (casadas o en unin consensuada) que no estn embarazadas ni son amenorreicas posparto, y que o bien no quieren tener ms hijos (quieren limitar el tamao de la familia), o bien desean posponer el nacimiento de un hijo durante al menos dos aos o no saben cundo o si quieren tener otro hijo (quieren espaciar los nacimientos), pero no estn utilizando ningn mtodo anticonceptivo.</p>\n        <p>Los mtodos modernos incluyen la esterilizacin femenina y masculina, el dispositivo intrauterino (DIU), el implante, los inyectables, las pldoras anticonceptivas orales, los preservativos masculinos y femeninos, los mtodos vaginales de barrera (incluidos el diafragma, el capuchn cervical y la espuma, la jalea, la crema y la esponja espermicida), el mtodo de amenorrea de la lactancia (LAM, por su sigla en ingls), la anticoncepcin de emergencia y otros mtodos modernos no informados por separado.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mtodo de estimacin</p>\n      </td>\n      <td>\n        <p>La Divisin de Poblacin de las Naciones Unidas produce una serie sistemtica y completa de estimaciones y proyecciones anuales del porcentaje de demanda de planificacin familiar que se satisface entre las mujeres casadas o unidas. Se utiliza un modelo jerrquico bayesiano combinado con datos especficos de cada pas para generar las estimaciones, proyecciones y evaluaciones de incertidumbre a partir de los datos de las encuestas. El modelo tiene en cuenta las diferencias segn la fuente de datos, la poblacin de la muestra y los mtodos anticonceptivos.</p>\n        <p>Vea aqu los detalles: <a href=\"http://www.un.org/en/development/desa/population/theme/family-planning/cp_model.shtml\">http://www.un.org/en/development/desa/population/theme/family-planning/cp_model.shtml</a></p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Notas relacionadas con la CSU</p>\n      </td>\n      <td>\n     </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>rea del trazador</p>\n      </td>\n      <td>\n        <p>Atencin al embarazo y al parto</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Definicin del indicador</p>\n      </td>\n      <td>\n        <p>Porcentaje de mujeres de entre 15 y 49 aos con un nacimiento vivo en un periodo de tiempo determinado que recibieron atencin prenatal cuatro o ms veces</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numerador</p>\n      </td>\n      <td>\n        <p>Nmero de mujeres de 15&#x2212;49 aos con un nacimiento vivo en un perodo de tiempo determinado que recibieron atencin prenatal cuatro o ms veces</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Denominador</p>\n      </td>\n      <td>\n        <p>Nmero total de mujeres de 15&#x2212;49 aos con un nacimiento vivo en el mismo perodo</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Principales fuentes de datos</p>\n      </td>\n      <td>\n        <p>Encuestas a hogares y sistemas de informacin rutinarios de los establecimientos</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mtodo de medicin</p>\n      </td>\n      <td>\n        <p>Los datos sobre cuatro o ms visitas de atencin prenatal se basan en preguntas que consultan si se control la salud de la mujer durante el embarazo y cuntas veces. Las encuestas a hogares que pueden generar este indicador incluyen DHS, MICS, RHS (por sus siglas en ingls) y otras encuestas basadas en metodologas similares. Los sistemas de notificacin de servicios/centros pueden utilizarse cuando la cobertura es alta, normalmente en los pases de ingresos ms altos.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mtodo de estimacin</p>\n      </td>\n      <td>\n        <p>La OMS mantiene una base de datos sobre la cobertura de la atencin prenatal: <a href=\"http://apps.who.int/gho/data/node.main.ANTENATALCARECOVERAGE4\">http://apps.who.int/gho/data/node.main.ANTENATALCARECOVERAGE4</a>.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Notas relacionadas con la CSU</p>\n      </td>\n      <td>\n        <p>En principio, este indicador se sustituira por una medida ms exhaustiva de la atencin al embarazo y al parto, por ejemplo, la proporcin de mujeres que tienen un proveedor cualificado que asiste al parto o un parto institucional. Un reto a la hora de medir la asistencia cualificada al parto es determinar qu proveedores son &#x201C;calificados&#x201D;.</p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<p><br></p>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>rea del trazador</p>\n      </td>\n      <td>\n        <p>Inmunizacin infantil</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Definicin del indicador</p>\n      </td>\n      <td>\n        <p>Porcentaje de lactantes que reciben tres dosis de la vacuna que contiene difteria-ttanos-tos ferina.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numerador</p>\n      </td>\n      <td>\n        <p>Nios de 1 ao de edad que han recibido tres dosis de la vacuna que contiene difteria-ttanos-tos ferina.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Denominador</p>\n      </td>\n      <td>\n        <p>Todos los nios de 1 ao de edad.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Principales fuentes de datos.</p>\n      </td>\n      <td>\n        <p>Encuestas a hogares y sistemas de informacin de instalaciones.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mtodo de medicin.</p>\n      </td>\n      <td>\n        <p>Para los datos de la encuesta, el estado de vacunacin de los nios de 12&#x2013;23 meses se recopila de las tarjetas de salud infantil o, si no hay tarjeta, del recuerdo del cuidador. Para los datos administrativos, se extrae el nmero total de dosis administradas a la poblacin objetivo.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mtodo de estimacin</p>\n      </td>\n      <td>\n        <p>Juntos, la OMS y el UNICEF obtienen estimaciones de la cobertura de la DTP3 basadas en los datos comunicados oficialmente a la OMS y al UNICEF por los Estados Miembros, as como en los datos comunicados en la literatura publicada y gris. Tambin consultan a expertos locales -principalmente a los gestores nacionales del PAI y al personal de las oficinas regionales de la OMS- para obtener informacin adicional sobre el funcionamiento de servicios de inmunizacin locales especficos. Sobre la base de los datos disponibles, la consideracin de posibles sesgos y las contribuciones de los expertos locales, la OMS y el UNICEF determinan el nivel real ms probable de cobertura de inmunizacin </p>\n        <p>Para ms detalles, vase aqu:</p>\n        <p><a href=\"http://www.who.int/bulletin/volumes/87/7/08-053819/en/\">http://www.who.int/bulletin/volumes/87/7/08-053819/en/</a></p>\n        <p><a href=\"http://www.who.int/immunization/monitoring_surveillance/routine/coverage/en/index4.html\">http://www.who.int/immunization/monitoring_surveillance/routine/coverage/en/index4.html</a></p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Notas relacionadas con la CSU</p>\n      </td>\n      <td>\n        <p>Existe una variabilidad en los calendarios nacionales de vacunacin entre los pases. Teniendo en cuenta esto, una opcin para supervisar la inmunizacin completa de los nios es supervisar la fraccin de nios que reciben las vacunas incluidas en el calendario nacional de su pas. Una segunda opcin, que puede ser ms comparable entre pases y en el tiempo, es vigilar la cobertura de la DTP3 como indicador de la inmunizacin infantil completa. La vacuna que contiene difteria-ttanos-tos ferina suele incluir otras vacunas, por ejemplo, contra la hepatitis B y el Haemophilus influenza tipo B, y es una medida razonable del grado de solidez de la plataforma de vacunacin de un pas.</p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>rea del trazador</p>\n      </td>\n      <td>\n        <p>Tratamiento de nios (bsqueda de atencin por sntomas de neumona).</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Definicin del indicador</p>\n      </td>\n      <td>\n        <p>Porcentaje de nios menores de 5 aos con sospecha de neumona (tos y dificultad para respirar NO debidas a un problema en el pecho y a una nariz tapada) en las dos semanas anteriores a la encuesta llevados a un centro o proveedor de salud adecuado.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>.\n        <p>Numerador</p>\n      </td>\n      <td>\n        <p>Nmero de nios con sospecha de neumona en las dos semanas anteriores a la encuesta llevados a un proveedor de salud adecuado.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Denominador</p>\n      </td>\n      <td>\n        <p>Nmero de nios con sospecha de neumona en las dos semanas anteriores a la encuesta.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Principales fuentes de datos</p>\n      </td>\n      <td>\n        <p>Encuestas de hogares.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mtodo de medicin</p>\n      </td>\n      <td>\n        <p>Durante la Reunin de UNICEF/OMS sobre indicadores basados en encuestas de supervivencia infantil, celebrada en Nueva York el 17&#x2013;18 de junio de 2004, se recomend que las infecciones respiratorias agudas (IRA) se describieran como &#x201C;presunta neumona&#x201D; para reflejar mejor la causa probable y las intervenciones recomendadas. La definicin de presunta neumona utilizada en las Encuestas Demogrficas y de Salud (EDS) y en las Encuestas de Indicadores Mltiples por Conglomerados (MICS, por su sigla en ingls) fue elegida por el grupo y se basa en la percepcin de las madres de que un nio tiene tos, respira ms rpido de lo habitual con respiraciones cortas y rpidas o tiene dificultades para respirar, excluyendo a los nios que slo tenan la nariz tapada. La definicin de \"proveedor de atencin adecuada\" vara segn los pases.</p>\n        <p>La OMS mantiene una base de datos de observaciones a nivel de pas de las encuestas de hogares a la que se puede acceder aqu: <a href=\"http://apps.who.int/gho/data/node.main.38?lang=en\">http://apps.who.int/gho/data/node.main.38?lang=en</a>.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mtodo de estimacin</p>\n      </td>\n      <td>\n        <p>Actualmente no existen estimaciones comparables a nivel internacional para este indicador.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Notas relacionadas con la CSU</p>\n      </td>\n      <td>\n        <p>Este indicador no suele medirse en los pases de mayor renta con sistemas sanitarios bien establecidos.</p>\n        <p>Para los pases sin datos observados, la cobertura se estim a partir de una regresin que predice la cobertura de la bsqueda de atencin para los sntomas de la neumona (en la escala logit), obtenida de la base de datos de la OMS descrita anteriormente, en funcin del logaritmo de la tasa estimada de mortalidad por neumona en menores de cinco aos, que se puede encontrar aqu: <a href=\"https://www.who.int/healthinfo/global_burden_disease/estimates/en/index2.html\">https://www.who.int/healthinfo/global_burden_disease/estimates/en/index2.html</a>.</p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>rea del trazador</p>\n      </td>\n      <td>\n        <p>Tratamiento de la tuberculosis.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Definicin del indicador</p>\n      </td>\n      <td>\n        <p>Porcentaje de casos de incidencia de tuberculosis que se detectan y tratan con xito en un ao determinado.</p>\n      </td>\n    </tr>\n    <tr>.\n      <td>\n        <p>Numerador</p>\n      </td>\n      <td>\n        <p>Nmero de casos nuevos y de recada detectados en un ao determinado y tratados con xito.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Denominador</p>\n      </td>\n      <td>\n        <p>Nmero de casos nuevos y de recadas en el mismo ao.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Principales fuentes de datos</p>\n      </td>\n      <td>\n        <p>Sistemas de informacin de los centros, sistemas de vigilancia, encuestas de salud basadas en la poblacin con pruebas de diagnstico de la tuberculosis, registro de la tuberculosis y sistema de notificacin trimestral relacionado (o registros electrnicos de la tuberculosis)</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mtodo de medicin</p>\n      </td>\n      <td>\n        <p>Este indicador requiere tres insumos principales:</p>\n        <p>(1) El nmero de casos de tuberculosis nuevos y de recada diagnosticados y tratados en los programas nacionales de control de la tuberculosis y notificados a la OMS en un ao determinado.</p>\n        <p>(2) El nmero de casos incidentes de TB para el mismo ao, normalmente estimado por la OMS.</p>\n        <p>(3) Porcentaje de casos de tuberculosis tratados con xito (curados ms tratamiento completado) entre los casos de tuberculosis notificados a las autoridades sanitarias nacionales.</p>\n        <p>El indicador final = (1)/(2) x (3).</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mtodo de estimacin</p>\n      </td>\n      <td>\n        <p>Las estimaciones de la incidencia de la tuberculosis se elaboran mediante un proceso consultivo y analtico dirigido por la OMS y se publican anualmente. Estas estimaciones se basan en las notificaciones anuales de casos, las evaluaciones de la calidad y la cobertura de los datos de notificacin de la tuberculosis, las encuestas nacionales de prevalencia de la enfermedad de la tuberculosis y la informacin de los sistemas de registro de defunciones (vitales). Las estimaciones de incidencia para cada pas se derivan, utilizando uno o ms de los siguientes enfoques, dependiendo de los datos disponibles:</p>\n        <p>1. incidencia = notificaciones de casos/proporcin estimada de casos detectados;</p>\n        <p>2. incidencia = prevalencia/duracin de la enfermedad;</p>\n        <p>3. incidencia = muertes/proporcin de casos incidentes que fallecen.</p>\n        <p>Estas estimaciones de la incidencia de la tuberculosis se combinan con los datos notificados por los pases sobre el nmero de casos detectados y tratados, y el porcentaje de casos tratados con xito, como se ha descrito anteriormente.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Notas relacionadas con la CSU</p>\n      </td>\n      <td>\n        <p>Para calcular el indicador utilizando las estimaciones de la OMS, se puede acceder a los archivos necesarios aqu: <a href=\"http://www.who.int/tb/country/data/download/en/\">http://www.who.int/tb/country/data/download/en/</a>, y calcular el indicador como = c_cdr x c_new_tsr.</p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>rea del trazador</p>\n      </td>\n      <td>\n        <p>Tratamiento del VIH.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Definicin del indicador</p>\n      </td>\n      <td>\n        <p>Porcentaje de personas que viven con el VIH y que actualmente reciben terapia antirretroviral (ART).</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numerador</p>\n      </td>\n      <td>.\n        <p>Nmero de adultos y nios que estn recibiendo actualmente tratamiento antirretroviral al final del perodo de notificacin.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Denominador</p>\n      </td>\n      <td>\n        <p>Nmero de adultos y nios que viven con el VIH durante el mismo periodo.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Principales fuentes de datos</p>\n      </td>\n      <td>\n        <p>Sistemas de notificacin de los centros, sitios de vigilancia centinela, encuestas basadas en la poblacin.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mtodo de medicin</p>\n      </td>\n      <td>\n        <p>Numerador: El numerador puede generarse contando el nmero de adultos y nios que recibieron terapia combinada antirretroviral al final del periodo de notificacin. Los datos pueden recopilarse a partir de los registros de tratamiento antirretroviral de los centros o de los sistemas de gestin de suministros de medicamentos. A continuacin, se contabilizan y se transfieren a informes transversales mensuales o trimestrales que pueden agregarse a los totales nacionales. Los pacientes que reciben terapia antirretroviral en el sector privado y en el sector pblico deben incluirse en el numerador.</p>\n        <p>Denominador: Los datos sobre el nmero de personas infectadas por el VIH pueden proceder de encuestas de poblacin o, como es habitual en el frica subsahariana, de sistemas de vigilancia basados en las clnicas de atencin prenatal.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mtodo de estimacin</p>\n      </td>\n      <td>\n        <p>Las estimaciones de la cobertura del tratamiento antirretroviral entre las personas que viven con el VIH para el perodo 2000-2018 se derivan como parte de la ronda de estimacin de ONUSIDA de 2019.</p>\n        <p>Para estimar el nmero de personas que viven con el VIH a lo largo del tiempo en los pases con alta carga, ONU/SIDA, en colaboracin con los pases, utiliza un modelo epidmico (Spectrum) que combina los datos de vigilancia sobre la prevalencia con el nmero actual de pacientes que reciben tratamiento antirretroviral y las hiptesis sobre la historia natural de la progresin de la enfermedad del VIH.</p>\n        <p>Dado que la terapia antirretrovrica se recomienda ahora a todas las personas que viven con el VIH, el seguimiento de la cobertura de la terapia antirretrovrica es menos complicado que antes, cuando slo podan recibirla las personas con un determinado nivel de gravedad de la enfermedad.</p>\n        <p>Las estimaciones de la cobertura del TAR se pueden encontrar aqu: http://aidsinfo.unaids.org/.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Notas relacionadas con la CSU</p>\n      </td>\n      <td>\n        <p>No siempre se dispone de estimaciones comparables de la cobertura de la terapia antirretroviral en los pases de renta alta, en particular de las tendencias temporales.</p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>rea del trazador</p>\n      </td>\n      <td>\n        <p>Prevencin de la malaria.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Definicin del indicador</p>\n      </td>\n      <td>\n        <p>Porcentaje de la poblacin de las zonas donde la malaria es endmica que durmi con un mosquitero impregnado de insecticida la noche anterior.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numerador</p>\n      </td>\n      <td>\n        <p>Nmero de personas en zonas donde la malaria es endmica que durmieron bajo un MTI.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Denominador</p>\n      </td>\n      <td>\n        <p>Nmero total de personas en zonas donde la malaria es endmica.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Principales fuentes de datos</p>\n      </td>\n      <td>\n        <p>Los datos sobre el acceso y el uso de los mosquiteros por parte de los hogares provienen de encuestas a hogares representativas a nivel nacional, como las Encuestas Demogrficas y de Salud, las Encuestas de Indicadores Mltiples por Conglomerados y las Encuestas de Indicadores de Malaria. Los datos sobre el nmero de MTI entregados por los fabricantes a los pases son recopilados por Milliner Global Associates, y los datos sobre el nmero de MTI distribuidos dentro de los pases son comunicados por los Programas Nacionales de Control de la Malaria.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mtodo de medicin</p>\n      </td>\n      <td>\n        <p>Muchas encuestas nacionales recientes informan del nmero de MTI observados en cada hogar encuestado. Las tasas de propiedad pueden convertirse en la proporcin de personas que duermen bajo un MTI utilizando una relacin lineal entre el acceso y el uso que se ha derivado de 62 encuestas que recopilan informacin sobre ambos indicadores.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mtodo de estimacin</p>\n      </td>\n      <td>\n        <p>Se pueden utilizar modelos matemticos para combinar los datos de las encuestas a hogares sobre el acceso y el uso con la informacin sobre la entrega de MTI por parte de los fabricantes y la distribucin de MTI por parte de los programas nacionales de malaria para producir estimaciones anuales de la cobertura de MTI. La OMS utiliza este enfoque en colaboracin con el Proyecto Atlas del Paludismo. Los detalles metodolgicos se encuentran en el Anexo del Informe Mundial sobre el Paludismo 2015: <a href=\"http://www.who.int/malaria/publications/world-malaria-report-2015/report/en/\">http://www.who.int/malaria/publications/world-malaria-report-2015/report/en/</a>.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Notas relacionadas con la CSU</p>\n      </td>\n      <td>\n        <p>La OMS elabora estimaciones comparables de la cobertura de los MTI para 40 pases con alta carga. Para otros pases, la cobertura de los mosquiteros no se incluye en el ndice de cobertura de servicios de CSU debido a las limitaciones de los datos.</p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>rea del trazador</p>\n      </td>\n      <td>\n        <p>Agua y saneamiento.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Definicin del indicador</p>\n      </td>\n      <td>\n        <p>Porcentaje de hogares que utilizan al menos instalaciones de saneamiento bsico.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numerador</p>\n      </td>\n      <td>\n        <p>Poblacin que vive en un hogar con: cisterna o vaciado al sistema de alcantarillado por tuberas, fosa sptica o letrina de pozo; letrina de pozo mejorada y ventilada; letrina de pozo con losa; o inodoro de compostaje.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Denominador</p>\n      </td>\n      <td>\n        <p>Poblacin total.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Principales fuentes de datos</p>\n      </td>\n      <td>\n        <p>Encuestas a hogares y censos basados en la poblacin.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mtodo de medicin</p>\n      </td>\n      <td>\n        <p>Las respuestas a nivel de hogar, ponderadas por el tamao del mismo, se utilizan para calcular la cobertura de la poblacin.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mtodo de estimacin</p>\n      </td>\n      <td>\n        <p>El Programa Conjunto de Monitoreo de la OMS y el UNICEF ha elaborado estimaciones peridicas de la cobertura de al menos el saneamiento bsico para el monitoreo de los ODM. Despus de compilar una base de datos de fuentes de datos disponibles, para cada pas, se ajustan regresiones lineales simples a las series de datos del pas para obtener una estimacin dentro de la muestra, as como para producir una extrapolacin de 2 aos ms all del ltimo punto de datos disponible, despus de lo cual la cobertura se mantiene constante durante 4 aos y luego se asume que falta. Esto se hace por separado para las regiones urbanas y rurales, y luego se combina para obtener estimaciones de cobertura nacional. Los detalles de la metodologa y las estimaciones ms recientes pueden encontrarse aqu: http://www.wssinfo.org/.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Notas relacionadas con la CSU</p>\n      </td>\n      <td>\n        <p>El indicador de los ODS para el saneamiento (ODS 6.2.1) es una versin ampliada del indicador de los ODM, que incorpora la calidad de las instalaciones de saneamiento. No se utiliza para el seguimiento de la cobertura sanitaria universal debido a la menor disponibilidad de datos. Tambin podra considerarse un indicador conjunto que identifique la proporcin de hogares con acceso tanto a agua potable como a saneamiento.</p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>rea del trazador</p>\n      </td>\n      <td>\n        <p>Prevencin de enfermedades cardiovasculares.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Definicin del indicador</p>\n      </td>\n      <td>\n        <p>Prevalencia estandarizada por edad de presin arterial normal entre los adultos mayores de 18 aos, independientemente del estado de tratamiento.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numerador</p>\n      </td>\n      <td>\n        <p>Nmero de adultos de 18 aos o ms con presin arterial sistlica &lt;140 mm Hg y presin arterial diastlica &lt;90 mm Hg (independientemente del estado del tratamiento).</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Denominador</p>\n      </td>\n      <td>\n        <p>Nmero de adultos de 18 aos o ms.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Principales fuentes de datos</p>\n      </td>\n      <td>\n        <p>Estudios basados en la poblacin y sistemas de vigilancia.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mtodo de medicin</p>\n     </td>\n      <td>\n        <p>Se utilizan las fuentes de datos que registran la presin arterial medida (se excluyen los datos autodeclarados).&#xA0;Si se toman varias lecturas de presin arterial por participante, se descarta la primera lectura y se promedian las restantes.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mtodo de estimacin</p>\n      </td>\n      <td>\n        <p>Para producir estimaciones nacionales comparables, las observaciones de datos de prevalencia definidas en trminos de cortes alternativos de PAS y/o PAD se convierten en prevalencia de presin arterial elevada, definida como presin arterial sistlica &gt;=140 mm Hg o presin arterial diastlica &gt;=90 mm Hg utilizando ecuaciones de regresin. A continuacin, se ajusta un modelo jerrquico bayesiano a estos datos para calcular las prevalencias especficas por edad, sexo y pas, que tiene en cuenta las fuentes de datos nacionales frente a las sub-nacionales, las fuentes de datos urbanas frente a las rurales, y permite la variacin de la prevalencia segn la edad y el sexo. Las estimaciones estandarizadas por edad se obtienen aplicando las estimaciones brutas a la poblacin estndar de la OMS. Los detalles de los mtodos estadsticos se encuentran aqu: <a href=\"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31919-5/fulltext\">http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31919-5/fulltext</a>.</p>\n        <p>La OMS y la NCD Risk Factor Collaboration (NCD-RisC, por su sigla en ingls) han elaborado estimaciones comparables para este indicador hasta el ao 2015, que estn disponibles aqu. </p>\n        <p><a href=\"http://apps.who.int/gho/data/node.main.A875STANDARD?lang=en\">http://apps.who.int/gho/data/node.main.A875STANDARD?lang=en</a>.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Notas relacionadas con la CSU</p>\n      </td>\n      <td>\n        <p>Las estimaciones de prevalencia se convierten en la prevalencia de la presin arterial normal para su incorporacin al ndice CSU, de modo que un valor del 100% es el objetivo ptimo. Esto se calcula como: prevalencia de presin arterial normal = 1 &#x2013; prevalencia de presin arterial elevada. Las estimaciones anteriores se realizan por separado para hombres y mujeres; para el indicador de seguimiento de la CSU se calcula una media simple de los valores de hombres y mujeres.</p>\n        <p>La presin arterial normal es la suma del porcentaje de individuos que no tienen hipertensin y el porcentaje de individuos cuya hipertensin est controlada por la medicacin. La ausencia de hipertensin es el resultado de los esfuerzos de prevencin a travs de la promocin de la actividad fsica y las dietas saludables, as como de otros factores. La hipertensin controlada con medicacin es el resultado de un tratamiento eficaz. Este indicador es, por tanto, un indicador indirecto tanto de la promocin de la salud como de los servicios mdicos eficaces.</p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>rea del trazador</p>\n      </td>\n      <td>\n        <p>Manejo de la diabetes</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Definicin del indicador</p>\n      </td>\n      <td>\n        <p>Glucosa plasmtica media en ayunas estandarizada por edad para adultos de 18 aos o ms.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Fuentes de datos principales</p>\n      </td>\n      <td>\n        <p>Estudios basados en la poblacin y sistemas de vigilancia.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mtodo de medicin</p>\n      </td>\n      <td>\n        <p>Los niveles de glucosa plasmtica en ayunas (FPG, segn su sigla en ingls) se determinan tomando una muestra de sangre de los participantes que han ayunado durante al menos 8 horas. Se utilizaron otros biomarcadores relacionados, como la hemoglobina A1c (HbA1c), para ayudar a calcular las estimaciones (vase ms adelante).<p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mtodo de estimacin</p>\n      </td>\n      <td>\n        <p>Para producir estimaciones nacionales comparables, las observaciones de datos basadas en la FPG media, la prueba de tolerancia a la glucosa oral (OGTT, segn su sigla en ingls), la HbA1c, o sus combinaciones, se convierten todas en FPG media. A continuacin, se ajusta un modelo jerrquico bayesiano a estos datos para calcular las prevalencias especficas por edad, sexo y pas, que tiene en cuenta las fuentes de datos nacionales frente a las sub-nacionales, las fuentes de datos urbanas frente a las rurales, y permite la variacin de la prevalencia segn la edad y el sexo. Las estimaciones estandarizadas por edad se obtienen aplicando las estimaciones brutas a la poblacin estndar de la OMS. Los detalles metodolgicos se pueden encontrar aqu: <a href=\"https://www.who.int/diabetes/global-report/en/\">https://www.who.int/diabetes/global-report/en/</a>.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Notas relacionadas con la CSU</p>\n      </td>\n      <td>\n        <p>La FPG de un individuo puede ser baja debido a un tratamiento eficaz con medicacin reductora de la glucosa, o porque el individuo no es diabtico como resultado de actividades de promocin de la salud u otros factores como la gentica. La FPG media es, por tanto, un indicador de la promocin efectiva de dietas y comportamientos saludables y del tratamiento efectivo de la diabetes.</p>\n        <p>Las estimaciones anteriores se realizan por separado para hombres y mujeres; para el indicador de seguimiento de la CSU se calcula una media simple de los valores para hombres y mujeres.</p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>rea del trazador</p>\n      </td>\n      <td>\n        <p>Control del tabaco.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Definicin del indicador</p>\n      </td>\n      <td>\n        <p>Prevalencia estandarizada por edad de adultos &gt;=15 aos que no han fumado tabaco en los ltimos 30 das.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numerador</p>\n      </td>\n      <td>\n        <p>Adultos de 15 aos o ms que no han fumado tabaco en los ltimos 30 das.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Denominador</p>\n      </td>\n      <td>\n        <p>Adultos de 15 aos o ms.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Principales fuentes de datos</p>\n      </td>\n      <td>\n        <p>Encuestas a hogares.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mtodo de medicin</p>\n      </td>\n      <td>\n        <p>&#x201C;El consumo actual de tabaco&quot; incluye cigarrillos, puros, pipas o cualquier otro producto de tabaco fumado consumido en los ltimos 30 das. Los datos se recopilan mediante autoinforme en las encuestas.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mtodo de estimacin</p>\n      </td>\n      <td>\n        <p>La OMS estima la prevalencia del tabaquismo actual (no) con un modelo de metarregresin binomial negativa, que genera estimaciones comparables ajustando las diferencias en los grupos de edad y la definicin de los indicadores entre las encuestas nacionales incluidas en el anlisis. Estas estimaciones se realizan por separado para hombres y mujeres. Los detalles metodolgicos se pueden encontrar aqu: <a href=\"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)60264-1/supplemental\">http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)60264-1/supplemental</a>.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Notas relacionadas con la CSU</p>\n      </td>\n      <td>\n        <p>La prevalencia de no fumar tabaco se calcula como 1 menos la prevalencia de fumar tabaco.</p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>rea del trazador</p>\n      </td>\n      <td>\n        <p>Acceso al hospital.</p>\n      </td>\n    </tr>\n    <tr>.\n      <td>\n        <p>Definicin del indicador</p>\n      </td>\n      <td>\n        <p>Camas hospitalarias per cpita, en relacin con un umbral mximo de 18 por cada 10.000 habitantes.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numerador</p>\n      </td>\n      <td>\n        <p>Nmero de camas de hospital (debe excluir las camas de parto).</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Denominador</p>\n      </td>\n      <td>.\n        <p>Poblacin total.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Principales fuentes de datos</p>\n      </td>\n      <td>\n        <p>Sistemas administrativos / Sistema de notificacin de los centros de salud.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mtodo de medicin</p>\n      </td>\n      <td>\n        <p>Se utilizan los sistemas administrativos de los pases para totalizar el nmero de camas de hospital, que se dividen por la poblacin total estimada, y se multiplican por 10.000.</p>\n        <p>Las oficinas regionales de la OMS y otros grupos recopilan informacin sobre la densidad nacional de camas hospitalarias, incluyendo los siguientes recursos en lnea:</p>\n        <p><a href=\"https://rho.emro.who.int/rhodata/node.main.A36\">https://rho.emro.who.int/rhodata/node.main.A36</a>.</p>\n        <p>Observatorio regional AFRO de la OMS: <a href=\"http://www.aho.afro.who.int/en/data-statistics/hospital-beds-10-000-population\">http://www.aho.afro.who.int/en/data-statistics/hospital-beds-10-000-population</a></p>\n        <p>Base de datos europea de salud para todos EURO de la OMS: <a href=\"https://gateway.euro.who.int/en/datasets%20european-health-for-all-database/\">https://gateway.euro.who.int/en/datasets european-health-for-all-database/</a>.</p>\n        <p>OCDE: <a href=\"https://data.oecd.org/healtheqt/hospital-beds.htm\">https://data.oecd.org/healtheqt/hospital-beds.htm</a>.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mtodo de estimacin</p>\n      </td>\n      <td>\n        <p>Utilizando los datos disponibles, el indicador se calcula en relacin con un valor umbral de 18 camas de hospital por cada 10.000 habitantes. Este umbral est por debajo del mnimo observado en los pases de renta alta de la OCDE (desde el ao 2000) de 20 por 10.000 y suele corresponder a una tasa de ingresos hospitalarios de alrededor de 5 por 100 al ao. Este indicador est diseado para captar niveles bajos de capacidad hospitalaria; el umbral mximo se utiliza porque las densidades de camas hospitalarias muy altas no son necesariamente un uso eficiente de los recursos. El indicador se calcula de la siguiente manera, utilizando los datos del pas sobre la densidad de camas hospitalarias (<em>x</em>), lo que da como resultado valores que van de 0 a 100:</p>\n        <p>Pas con una densidad de camas hospitalarias <em>x</em> &lt; 18 por 10.000 al ao, el indicador = </p>\n        <p><em>x</em> /18*100.</p>\n        <p>Pas con una densidad de camas hospitalarias <em>x</em> &gt;= 18 por 10.000 al ao, el indicador = 100.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Notas relacionadas con la CSU</p>\n      </td>\n      <td>\n        <p>Un indicador alternativo podra ser la tasa de ingresos hospitalarios, en relacin con un umbral mximo. Sin embargo, ese indicador no se comunica actualmente de forma generalizada en todas las regiones, en particular en la Regin de frica. En los pases en los que se dispone tanto de camas de hospital per cpita como de tasas de admisin de pacientes internos, estn muy correlacionados.</p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>rea del trazador</p>\n      </td>\n      <td>\n        <p>Personal sanitario.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Definicin del indicador</p>\n      </td>\n      <td>\n        <p>Profesionales de la salud (mdicos, psiquiatras y cirujanos) per cpita, en relacin con los umbrales mximos de cada cuadro.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numerador</p>\n      </td>\n      <td>\n        <p>Nmero de mdicos, psiquiatras y cirujanos.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Denominador</p>\n      </td>\n      <td>\n        <p>Poblacin total.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Principales fuentes de datos</p>\n      </td>\n      <td>\n        <p>Base de datos o registro nacional de personal sanitario, idealmente acoplado a una evaluacin peridica de la exhaustividad mediante datos censales, registros de asociaciones profesionales o censos de centros.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mtodo de medicin</p>\n      </td>\n      <td>\n        <p>La clasificacin de los trabajadores sanitarios se basa en criterios de formacin profesional, regulacin de las profesiones sanitarias y actividades y tareas de los puestos de trabajo, es decir, en un marco de categorizacin de las variables clave de la fuerza de trabajo segn caractersticas compartidas. El marco de la OMS se basa en gran medida en las ltimas revisiones de los sistemas de clasificacin normalizados internacionalmente de la Organizacin Internacional del Trabajo (Clasificacin Internacional Uniforme de Ocupaciones), la Organizacin de las Naciones Unidas para la Educacin, la Ciencia y la Cultura (Clasificacin Internacional Uniforme de la Enseanza) y la Divisin de Estadsticas de las Naciones Unidas (Clasificacin Industrial Internacional Uniforme de Todas las Actividades Econmicas). </p>\n        <p>Los detalles metodolgicos y los datos pueden encontrarse aqu: <a href=\"http://www.who.int/hrh/statistics/hwfstats/en/\">http://www.who.int/hrh/statistics/hwfstats/en/</a>.</p>\n        <p>Los datos proceden de las siguientes fuentes:</p>\n        <p>Mdicos: <a href=\"http://apps.who.int/gho/data/node.main.HWFGRP_0020?lang=en\">http://apps.who.int/gho/data/node.main.HWFGRP_0020?lang=en</a>.</p>\n        <p>Psiquiatras: <a href=\"https://www.who.int/healthinfo/universal_health_coverage/report/2017/en/\">https://www.who.int/healthinfo/universal_health_coverage/report/2017/en/</a>.</p>\n        <p>Cirujanos: <a href=\"http://apps.who.int/gho/data/node.main.HWF9?lang=en%20\">http://apps.who.int/gho/data/node.main.HWF9?lang=en</a>.<p>\n        <p>(los datos aqu fueron complementados por ediciones anteriores de la base de datos).</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mtodo de estimacin</p>\n      </td>\n      <td>\n        <p>Utilizando los datos disponibles, el indicador se calcula reescalando primero, por separado, los ratios de densidad de personal sanitario para cada uno de los tres cuadros (mdicos, psiquiatras y cirujanos) en relacin con los valores mnimos observados en todos los pases de la OCDE desde el ao 2000, que son los siguientes: mdicos = 0,9 por 1000, psiquiatras = 1 por 100.000 y cirujanos = 14 por 100.000. Este reajuste se realiza de la misma manera que el del indicador de densidad de camas hospitalarias descrito anteriormente, lo que da como resultado valores del indicador que van de 0 a 100 para cada uno de los tres cuadros. Por ejemplo, utilizando los datos del pas sobre los mdicos por cada 1000 habitantes (<em>x</em>), el indicador especfico de los cuadros se calculara como:</p>\n        <p>Pas con <em>x</em> &lt; 0,9 por 1000 al ao, el indicador especfico de cuadro = <em>x</em> /0,9*100.</p>\n        <p>Pas con <em>x</em> &gt;= 0,9 por 1000 al ao, el indicador especfico de cuadro = 100.</p>\n        <p>Como paso final, se calcula la media geomtrica de los tres valores del indicador especfico de cuadro para obtener el indicador final de densidad de personal sanitario.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Notas relacionadas con la CSU</p>\n      </td>\n      <td>\n        <p>La categora de &#x201C;mdicos&#x201D; se ampliara idealmente para incluir a todos los &#x201C;profesionales sanitarios bsicos&#x201D;, como las enfermeras y las comadronas. Sin embargo, no existe ninguna base de datos comparable a nivel internacional que utilice definiciones coherentes de los profesionales sanitarios bsicos no mdicos para poder realizar comparaciones totalmente precisas entre pases.</p>\n        <p>Para los pases sin datos observados, la densidad de cirujanos se estim a partir de una regresin que predice el logaritmo de cirujanos por cada 100.000, obtenida de la base de datos de la OMS descrita anteriormente, en funcin del logaritmo del PIB per cpita, estimado por el Banco Mundial.</p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>rea del trazador</p>\n      </td>\n      <td>\n        <p>Seguridad sanitaria.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Definicin del indicador</p>\n      </td>\n      <td>\n        <p>ndice de capacidad bsica del Reglamento Sanitario Internacional (RSI), que es el porcentaje medio de atributos de 13 capacidades bsicas que se han alcanzado en un momento determinado.</p>\n        <p>Las 13 capacidades bsicas son: (1) Legislacin, poltica y financiacin nacional; (2) Coordinacin y comunicaciones del Punto Focal Nacional; (3) Vigilancia; (4) Respuesta; (5) Preparacin; (6) Comunicacin de riesgos; (7) Recursos humanos; (8) Laboratorio; (9) Puntos de entrada; (10) Eventos zoonticos; (11) Seguridad alimentaria; (12) Eventos qumicos; (13) Emergencias radionucleares.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numerador</p>\n      </td>\n      <td>\n        <p>Nmero de atributos alcanzados.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Denominador</p>\n      </td>\n      <td>\n        <p>Nmero total de atributos.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Principales fuentes de datos</p>\n      </td>\n      <td>\n        <p>Encuesta a informantes clave.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mtodo de medicin</p>\n      </td>\n      <td>\n        <p>Los informantes clave informan sobre el logro de un conjunto de atributos para cada una de las 13 capacidades bsicas utilizando un instrumento estndar de la OMS, como se describe aqu: <a href=\"http://apps.who.int/iris/bitstream/10665/84933/1/WHO_HSE_GCR_2013.2_eng.pdf\">http://apps.who.int/iris/bitstream/10665/84933/1/WHO_HSE_GCR_2013.2_eng.pdf</a>.</p>\n        <p>Los valores de los indicadores a nivel de capacidad se pueden encontrar aqu:</p>\n        <p><a href=\"http://apps.who.int/gho/data/node.main.IHRSPARALL?lang=en\">http://apps.who.int/gho/data/node.main.IHRSPARALL?lang=en</a>.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mtodo de estimacin</p>\n      </td>\n      <td>\n        <p>El indicador se calcula promediando, entre las 13 capacidades bsicas, el porcentaje de atributos de cada capacidad que se han alcanzado.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Notas relacionadas con la CSU</p>\n      </td>\n      <td>\n        <p>Los pases comenzaron a informar a la OMS sobre el logro de la capacidad bsica del RSI para el ao 2010. Se utiliza la puntuacin del RSI ms antigua disponible para cada pas para todos los aos 2000-2009.</p>\n      </td>\n    </tr>\n  </tbody>\n</table>","fr":"<p>(Toutes les rfrences sont en anglais,  moins d'indication contraire)</p>\n<p><strong>URL : </strong><a href=\"http://www.who.int/healthinfo/universal_health_coverage/en/\"><u>http://www.who.int/healthinfo/universal_health_coverage/en/</u></a></p>\n<p> </p>\n<p><strong>Rfrences : </strong>Rapport mondial de suivi 2017 : la couverture-sant universelle <a href=\"https://www.who.int/fr/publications/i/item/WHO-HIS-HGF-17.2\">https://www.who.int/fr/publications/i/item/WHO-HIS-HGF-17.2</a></p>\n<p><a href=\"http://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X(17)30472-2.pdf\" target=\"_blank\"><u>http://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X(17)30472-2.pdf</u></a> </p>\n<p><a href=\"http://www.who.int/healthinfo/universal_health_coverage/en/\" target=\"_blank\"><u>http://www.who.int/healthinfo/universal_health_coverage/en/</u></a> </p>\n<p>Pour le dveloppement historique de mthodes, consulter :</p>\n<p><a href=\"http://www.who.int/healthinfo/universal_health_coverage/UHC_WHS2016_TechnicalNote_May2016.pdf?ua=1\">http://www.who.int/healthinfo/universal_health_coverage/UHC_WHS2016_TechnicalNote_May2016.pdf?ua=1</a> (remplac par le document)</p>\n<p><a href=\"http://www.who.int/healthinfo/universal_health_coverage/report/2015/en/\">http://www.who.int/healthinfo/universal_health_coverage/report/2015/en/</a></p>\n<p><a href=\"http://www.who.int/healthinfo/universal_health_coverage/report/2014/en/\">http://www.who.int/healthinfo/universal_health_coverage/report/2014/en/</a></p>\n<p><a href=\"http://collections.plos.org/uhc2014\">http://collections.plos.org/uhc2014</a></p>\n<p> </p>\n<p>Annexe 1: Metadonnes pour les indicateurs traceurs utiliss pour mesurer la couverture des services de sant essentiels pour suivre l'indicateur des ODD 3.8.1.</p>\n<p>Veuillez envoyer vos commentaires ou requtes  l'adresse : <a href=\"mailto:uhc_stats@who.int\">uhc_stats@who.int</a></p>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>Indicateur traceur</p>\n      </td>\n      <td>\n        <p>Planification familiale</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Dfinition de l'indicateur</p>\n      </td>\n      <td>\n        <p>Pourcentage de femmes en ge de procrer (15  49 ans) maries ou en\nunion libre qui ont besoin dune planification familiale satisfaite par des mthodes modernes.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numrateur</p>\n      </td>\n      <td>\n        <p>Nombre de femmes ges de 15  49 ans, maries ou en union libre, qui\nutilisent des mthodes modernes</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Dnominateur</p>\n      </td>\n      <td>\n        <p>Nombre total de femmes ges de 15  49 ans, maries ou en union libre,\nqui ont besoin de planification familiale</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Sources principales de donnes</p>\n      </td>\n      <td>\n        <p>Enqute de populaiton sur la sant</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mthode de mesure</p>\n      </td>\n      <td>\n        <p>Les enqutes auprs des mnages comprennent une srie de questions pour\nmesurer le taux de prvalence de la contraception moderne et la demande de planification familiale. La demande totale de planification familiale est dfinie comme la somme du nombre de femmes en ge de procrer (15-49 ans) qui sont maries ou en union libre et qui utilisent actuellement, ou dont le partenaire sexuel utilise actuellement, au moins une mthode contraceptive , et le besoin non satisfait de planification familiale. Le besoin non satisfait de planification familiale est la proportion de femmes en ge de procrer (15-49 ans) maries ou en union libre, qui sont fcondes et sexuellement actives mais qui n'utilisent aucune mthode de contraception (moderne ou traditionnelle) et qui dclarent ne plus vouloir d'enfant ou vouloir retarder la naissance de leur prochain enfant d'au moins deux ans. Sont incluses :</p>\n         <ol>\n          <li>toutes les femmes enceintes (maries ou en union libre) dont les grossesses\ntaient non dsires ou inopportunes au moment de la conception;</li>\n          <li>toutes les femmes en amnorrhe post-partum (maries ou en union libre)\nqui n'utilisent pas la planification familiale et dont le dernier accouchement n'tait pas dsir ou inopportun;</li>\n          <li>toutes les femmes fcondes (maries ou en union libre) qui ne sont\nni enceintes ni en amnorrhe post-partum, et qui soit ne veulent plus d'enfants (veulent limiter la taille de la famille), soit qui souhaitent reporter la naissance d'un enfant d'au moins deux ans ou ne savent pas quand ou si elles veulent un autre enfant (veulent espacer les naissances), mais n'utilisent aucune mthode contraceptive.</li> </ol>\n        <p>Les mthodes modernes comprennent la strilisation fminine et masculine,\nle dispositif intra-utrin (DIU), l'implant, les injectables, les pilules contraceptives orales, les prservatifs masculins et fminins, les mthodes de barrire vaginale (y compris le diaphragme, la cape cervicale et la mousse spermicide, la gele, la crme et l'ponge), la mthode de l'allaitement maternel et de l'amnorrhe (MAMA), la contraception d'urgence et d'autres mthodes modernes non dclares sparment.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mthode d'estimation</p>\n      </td>\n      <td>\n        <p>La Division de la population des Nations Unies produit une srie systmatique\net complte d'estimations et de projections annuelles du pourcentage de la demande de planification familiale qui est satisfaite chez les femmes maries ou en union libre. Un modle hirarchique baysien combin  des donnes spcifiques au pays est utilis pour gnrer les estimations, les projections et les valuations de l'incertitude  partir des donnes d'enqute. Le modle tient compte des diffrences selon la source de donnes, l'chantillon de population et les mthodes contraceptives. </p>\n        <p>Pour plus de dtails, consulter :</p>\n        <p>https://www.un.org/development/desa/pd/data/family-planning-indicators</p>\n        <p>Compilation de donnes d'enqutes par pays sur l'utilisation mondiale\nde contraceptifs : </p>\n        <p>https://www.un.org/development/desa/pd/node/3285 </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Notes au sujet de la CSU</p>\n      </td>\n      <td></td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>Indicateur traceur</p>\n      </td>\n      <td>\n        <p>Soins de grossesse et daccouchement</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Dfinition de l'indicateur</p>\n      </td>\n      <td>\n        <p>Pourcentage de femmes ges de 15  49 ans ayant accouch (naissance\nvivante) au cours dune priode donne et qui ont reu des soins prnatals quatre fois ou plus </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numrateur</p>\n      </td>\n      <td>\n        <p>Nombre de femmes ges de 15  49 ans ayant accouch (naissance vivante)\nau cours dune priode donne et qui ont reu des soins prnatals quatre fois ou plus</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Dnominateur</p>\n      </td>\n      <td>\n        <p>Nombre total de femmes ges de 15  49 ans ayant accouch (naissance\nvivante) au cours de cette mme priode</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Sources principales de donnes</p>\n      </td>\n      <td>\n        <p>Enqutes auprs des mnages et systme d'information de routine des tablissements</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mthode de mesure</p>\n      </td>\n      <td>\n        <p>Les donnes sur quatre consultations prnatales ou plus sont bases sur\ndes questions qui demandent si et combien de fois la sant de la femme a t contrle pendant la grossesse. Les enqutes auprs des mnages qui peuvent gnrer cet indicateur comprennent les EDS, MICS, RHS et d'autres enqutes bases sur des mthodologies similaires. Les systmes de notification des services/tablissements peuvent tre utiliss l o la couverture est leve, gnralement dans les pays  revenu lev.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mthode d'estimation</p>\n      </td>\n      <td>\n        <p>L'OMS tient  jour une base de donnes sur la couverture des soins prnatals\n: <a href=\"http://apps.who.int/gho/data/node.main.ANTENATALCARECOVERAGE4\"><u>http://apps.who.int/gho/data/node.main.ANTENATALCARECOVERAGE4</u></a></p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Notes au sujet de la CSU</p>\n      </td>\n      <td>\n        <p>Idalement, cet indicateur devrait tre remplac par une mesure plus\ncomplte des soins pendant la grossesse et l'accouchement, par exemple la proportion de femmes qui ont un prestataire qualifi pour assister  l'accouchement ou  un accouchement en institution. Un dfi dans la mesure de l'assistance qualifie  l'accouchement consiste  dterminer quels prestataires sont qualifis. </p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<p><br></p>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>Indicateur traceur</p>\n      </td>\n      <td>\n        <p>Vaccination des enfants</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Dfinition de l'indicateur</p>\n      </td>\n      <td>\n        <p>Pourcentage de nourrissons recevant trois doses du vaccin diphtrie-ttanos-coqueluche</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numrateur</p>\n      </td>\n      <td>\n        <p>Nombre d'enfants de 1 an ayant reu trois doses du vaccin diphtrie-ttanos-coqueluche</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Dnominateur</p>\n      </td>\n      <td>\n        <p>Nombre total d'enfants de 1 an</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Sources principales de donnes</p>\n      </td>\n      <td>\n        <p>Enqutes auprs des mnages et systme d'information de routine des tablissements</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mthode de mesure</p>\n      </td>\n      <td>\n        <p>Pour les donnes d'enqute, le statut vaccinal des enfants gs de 12\n 23 mois est recueilli  partir des carnets de sant de l'enfant ou,  dfaut de carnet,  partir du rappel par la personne en charge de l'enfant. Pour les donnes administratives, le nombre total de doses administres  la population cible est extrait.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mthode d'estimation</p>\n      </td>\n      <td>\n        <p>Ensemble, l'OMS et l'UNICEF drivent des estimations de la couverture\ndu DTC3 sur la base des donnes officiellement communiques  l'OMS et  l'UNICEF par les tats membres, ainsi que des donnes dclares dans la littrature publie et la littrature grise. Ils consultent galement des experts locaux - principalement les responsables nationaux du Programme tendu de vaccination et le personnel des bureaux rgionaux de l'OMS - pour obtenir des informations supplmentaires concernant la performance de services de vaccination locaux spcifiques. Sur la base des donnes disponibles, de la prise en compte des biais potentiels et des contributions d'experts locaux, l'OMS/UNICEF dtermine le niveau rel le plus probable de couverture vaccinale. </p>\n        <p>Pour plus de dtails, consulter : </p>\n        <p>http://www.who.int/bulletin/volumes/87/7/08-053819/en/</p>\n        <p>http://www.who.int/immunization/monitoring_surveillance/routine/coverage/en/index4.html</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Notes au sujet de la CSU</p>\n      </td>\n      <td>\n        <p>Les calendriers nationaux de vaccination varient d'un pays  l'autre.\nCompte tenu de cela, une option pour surveiller la vaccination complte des enfants consiste  surveiller la fraction d'enfants recevant des vaccins inclus dans le calendrier national de leur pays. Une deuxime option, qui peut tre plus comparable d'un pays  l'autre et dans le temps, consiste  surveiller la couverture par le DTC3 comme indicateur indirect de la vaccination complte des enfants. Le vaccin contenant la diphtrie, le ttanos et la coqueluche comprend souvent d'autres vaccins, par exemple contre l'hpatite B et l'Haemophilus influenza de type B, et constitue une mesure raisonnable  savoir s'il existe une plate-forme de distribution de vaccins robuste dans un pays.</p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>Indicateur traceur</p>\n      </td>\n      <td>\n        <p>Traitement de lenfant (recherche de soins pour des symptmes de pneumonie)</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Dfinition de l'indicateur</p>\n      </td>\n      <td>\n        <p>Pourcentage denfants de moins de 5 ans qu'on considre atteints dune\npneumonie (toux et respiration difficile NON en raison dun problme dans la poitrine et d'un nez obstru) dans les deux semaines prcdant lenqute et qui ont t amens dans un tablissement ou fournisseur de sant appropri.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numrateur</p>\n      </td>\n      <td>\n        <p>Nombre denfants qu'on considre atteints dune pneumonie dans les deux\nsemaines prcdant lenqute et qui ont t amens dans un tablissement de sant appropri</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Dnominateur</p>\n      </td>\n      <td>\n        <p>Nombre denfants qu'on considre atteints dune pneumonie dans les deux\nsemaines prcdant lenqute</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Sources principales de donnes</p>\n      </td>\n      <td>\n        <p>Enqutes auprs des mnages</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mthode de mesure</p>\n      </td>\n      <td>\n        <p>Au cours de la runion sur les indicateurs de survie de l'enfant bass\nsur les enqutes, de UNICEF/OMS, tenue  New York, les 17 et 18 juin 2004, il a t recommand que les infections respiratoires aigus (IRA) soient dcrites comme une pneumonie prsume afin de mieux reflter la cause probable et les interventions recommandes. La dfinition de la pneumonie prsume utilise dans les Enqutes dmographiques et de sant (EDS) et dans les Enqutes en grappes  indicateurs multiples (MICS) a t choisie par le groupe et est base sur la perception des mres d'un enfant qui tousse, respire plus vite que d'habitude avec des respirations courtes et rapides ou ayant des difficults  respirer,  l'exclusion des enfants qui n'avaient que le nez bouch. La dfinition du prestataire de soins appropri varie d'un pays  l'autre.</p>\n        <p>L'OMS maintient une base de donnes d'observations au niveau des pays,\n partir d'enqutes auprs des mnages qui peut tre consulte  l'adresse : <a href=\"http://apps.who.int/gho/data/node.main.38?lang=en\"><u>http://apps.who.int/gho/data/node.main.38?lang=en</u></a></p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mthode d'estimation</p>\n      </td>\n      <td>\n        <p>Il n'existe actuellement aucune estimation comparable au niveau international\npour cet indicateur.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Notes au sujet de la CSU</p>\n      </td>\n      <td>\n        <p>Cet indicateur n'est gnralement pas mesur dans les pays  revenu lev\ndots de systmes de sant bien tablis. </p>\n        <p>Pour les pays sans donnes observes, la couverture a t estime  partir\nd'une rgression qui prdit la couverture de la recherche de soins pour des symptmes de pneumonie (sur l'chelle logit), obtenue  partir de la base de donnes de l'OMS dcrite ci-dessus, en fonction du log de l'estimation du taux de mortalit par pneumonie chez les moins de 5 ans, que vous pouvez trouver  l'adresse : <a href=\"https://www.who.int/healthinfo/global_burden_disease/estimates/en/index2.html\"><u>https://www.who.int/healthinfo/global_burden_disease/estimates/en/index2.html</u></a></p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>Indicateur traceur</p>\n      </td>\n      <td>\n        <p>Traitement pour la tuberculose</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Dfinition de l'indicateur</p>\n      </td>\n      <td>\n        <p>Pourcentage de cas de tuberculose dtects et traits dans une anne\ndonne</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numrateur</p>\n      </td>\n      <td>\n        <p>Nombre de nouveaux cas et de cas de rechute dtects et traits dans\nune anne donne</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Dnominateur</p>\n      </td>\n      <td>\n        <p>Nombre de nouveaux cas et de cas de rechute dtects au cours de cette\nmme anne</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Sources principales de donnes</p>\n      </td>\n      <td>\n        <p>Systmes d'information des tablissements, systmes de surveillance,\nenqutes de sant bases sur la population avec tests de diagnostic de la tuberculose, registre de la tuberculose et systme de notification trimestriel connexe (ou registres lectroniques de la tuberculose)</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mthode de mesure</p>\n      </td>\n      <td>\n        <p>Cet indicateur ncessite deux entres principales :</p>\n        <p>(1) Le nombre de nouveaux cas de tuberculose et de cas de rechute diagnostiqus\net traits dans les programmes nationaux de lutte contre la tuberculose et dclars  l'OMS au cours d'une anne donne .</p>\n        <p>(2) Le nombre de cas de tuberculose pour la mme anne, gnralement\nestim par l'OMS .</p>\n        <p>L'indicateur final = (1)/(2)</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mthode d'estimation</p>\n      </td>\n      <td>\n        <p>Les estimations de l'incidence de la tuberculose sont produites dans\nle cadre d'un processus consultatif et analytique dirig par l'OMS et sont publies chaque anne. Ces estimations sont bases sur les notifications annuelles de cas, les valuations de la qualit et de la couverture des donnes de notification de la tuberculose, les enqutes nationales sur la prvalence de la tuberculose et les informations provenant des systmes d'enregistrement des dcs (tat civil). Les estimations de l'incidence pour chaque pays sont drives, en utilisant une ou plusieurs des approches suivantes en fonction des donnes disponibles :</p>\n        <p>1. incidence = notifications de cas/proportion estime de cas dtects;</p>\n        <p>2. incidence = prvalence/dure de la condition;</p>\n        <p>3. incidence = dcs/proportion de cas qui rsultent en dcs. </p>\n        <p>Ces estimations de l'incidence de la tuberculose sont combines avec\nles donnes dclares par les pays sur le nombre de cas dtects et traits, et le pourcentage de cas traits avec succs, comme dcrit ci-dessus. .</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Notes au sujet de la CSU</p>\n      </td>\n      <td>\n        <p>Pour calculer l'indicateur  l'aide des estimations de l'OMS, on peut\naccder aux fichiers ncessaires  l'adresse : <a href=\"http://www.who.int/tb/country/data/download/en/\"><u>http://www.who.int/tb/country/data/download/en/</u></a>, et calculer l'indicateur comme tant = c_cdr</p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>Indicateur traceur</p>\n      </td>\n      <td>\n        <p>Traitement pour le VIH</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Dfinition de l'indicateur</p>\n      </td>\n      <td>\n        <p>Pourcentage de personnes vivant avec le VIH qui reoivent actuellement\nun traitement antirtroviral</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numrateur</p>\n      </td>\n      <td>\n        <p>Nombre d'adultes et d'enfants qui recevaient un traitement antirtroviral\n la fin de la priode de rfrence</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Dnominateur</p>\n      </td>\n      <td>\n        <p>Nombre d'adultes et d'enfants vivant avec le VIH pendant la mme priode</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Sources principales de donnes</p>\n      </td>\n      <td>\n        <p>Systmes de dclaration des tablissements, sites de surveillance sentinelle,\nenqutes bases sur la population </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mthode de mesure</p>\n      </td>\n      <td>\n        <p>Numrateur: Le numrateur peut tre gnr en comptant le nombre d'adultes\net d'enfants qui ont reu une polythrapie antirtrovirale  la fin de la priode de rfrence. Les donnes peuvent tre recueillies  partir des registres de traitement antirtroviral des tablissements ou des systmes de gestion de l'approvisionnement en mdicaments. Ceux-ci sont ensuite comptabiliss et transfrs dans des rapports mensuels ou trimestriels transversaux qui peuvent ensuite tre agrgs pour obtenir des totaux nationaux. Les patients recevant un traitement antirtroviral dans le secteur priv et le secteur public doivent tre inclus dans le numrateur.</p>\n        <p>Dnominateur: Les donnes sur le nombre de personnes infectes par le\nVIH peuvent provenir d'enqutes bases sur la population ou, comme c'est souvent le cas en Afrique subsaharienne, de systmes de surveillance bass sur des cliniques de soins prnatals.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mthode d'estimation</p>\n      </td>\n      <td>\n        <p>Les estimations de la couverture du traitement antirtroviral chez les\npersonnes vivant avec le VIH pour 2000-2018 sont drives du cycle d'estimation 2019 de l'ONUSIDA. </p>\n        <p>Pour estimer le nombre de personnes vivant avec le VIH au fil du temps\ndans les pays  forte charge, l'ONUSIDA, en collaboration avec les pays, utilise un modle pidmique (Spectrum) qui combine les donnes de surveillance sur la prvalence avec le nombre actuel de patients recevant un traitement antirtroviral et des hypothses sur l'histoire naturelle de l'volution du VIH. </p>\n        <p>tant donn que le traitement antirtroviral est dsormais recommand\npour toutes les personnes vivant avec le VIH, le suivi de la couverture de ce traitement est moins compliqu qu'auparavant, alors que seules les personnes prsentant un certain niveau de gravit de la maladie taient ligibles pour recevoir ce traitement.</p>\n        <p>Les estimations de la couverture du traitement antirtroviral sont disponibles\n l'adresse : http://aidsinfo.unaids.org/</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Notes au sujet de la CSU</p>\n      </td>\n      <td>\n        <p>Des estimations comparables de la couverture du traitement antirtroviral\ndans les pays  revenu lev, en particulier les tendances temporelles, ne sont pas toujours disponibles .</p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>Indicateur traceur</p>\n      </td>\n      <td>\n        <p>Prvention du paludisme (malaria)</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Dfinition de l'indicateur</p>\n      </td>\n      <td>\n        <p>Pourcentage de la population dans les zones o le paludisme est endmique\nqui dormait sous une moustiquaire imprgne dinsecticide la nuit prcdente.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numrateur</p>\n      </td>\n      <td>\n        <p>Nombre de personnes dans les zones o le paludisme est endmique qui\ndormaient sous une moustiquaire imprgne dinsecticide.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Dnominateur</p>\n      </td>\n      <td>\n        <p>Nombre total de personnes dans les zones o le paludisme est endmique.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Sources principales de donnes</p>\n      </td>\n      <td>\n        <p>Les donnes sur l'accs et l'utilisation des moustiquaires imprgnes\ndinsecticide (MII) par les mnages proviennent d'enqutes auprs des mnages reprsentatives au niveau national telles que les enqutes dmographiques et de sant, les enqutes en grappes  indicateurs multiples et les enqutes sur les indicateurs du paludisme. Les donnes sur le nombre de MII livres par les fabricants aux pays sont compiles par Milliner Global Associates, et les donnes sur le nombre de MII distribues dans les pays sont communiques par les programmes nationaux de lutte contre le paludisme.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mthode de mesure</p>\n      </td>\n      <td>\n        <p>De nombreuses enqutes nationales rcentes rapportent le nombre de MII\nobserves dans chaque mnage rpondant. Les taux de possession peuvent tre convertis en proportion de personnes dormant sous une MII en utilisant une relation linaire entre l'accs et l'utilisation qui a t drive de 62 enqutes qui recueillent des informations sur les deux indicateurs. </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mthode d'estimation</p>\n      </td>\n      <td>\n        <p>Des modles mathmatiques peuvent tre utiliss pour combiner les donnes\ndes enqutes auprs des mnages sur l'accs et l'utilisation avec des informations sur les livraisons de MII par les fabricants et la distribution de MII par les programmes nationaux de lutte contre le paludisme afin de produire des estimations annuelles de la couverture en MII. L'OMS utilise cette approche en collaboration avec le Malaria Atlas Project. Les dtails mthodologiques peuvent tre trouvs dans l'annexe du Rapport mondial sur le paludisme 2015 : <u>https://apps.who.int/iris/handle/10665/200018</u>.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Notes au sujet de la CSU</p>\n      </td>\n      <td>\n        <p>L'OMS produit des estimations comparables de la couverture en MII pour\n40 pays fortement touchs. Pour les autres pays, la couverture en MII n'est pas incluse dans l'indice de couverture des services pour la CSU en raison des limites des donnes. </p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>Indicateur traceur</p>\n      </td>\n      <td>\n        <p>Eau et systme sanitaire</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Dfinition de l'indicateur</p>\n      </td>\n      <td>\n        <p>Pourcentage de mnages utilisant au moins des installations sanitaires\nde base</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numrateur</p>\n      </td>\n      <td>\n        <p>Population vivant dans un mnage avec : chasse d'eau vers un rseau d'gouts,\nune fosse septique ou des latrines  fosse; latrine  fosse ventile amliore; latrines  fosse avec dalle; ou toilettes  compost.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Dnominateur</p>\n      </td>\n      <td>\n        <p>Population totale</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Sources principales de donnes</p>\n      </td>\n      <td>\n        <p>Enqutes auprs des mnages et recensements</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mthode de mesure</p>\n      </td>\n      <td>\n        <p>Les rponses au niveau du mnage, pondres par la taille du mnage,\nsont utilises pour calculer la couverture de la population.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mthode d'estimation</p>\n      </td>\n      <td>\n        <p>Le Programme conjoint de suivi OMS/UNICEF rassemble, examine et value\nles donnes nationales recueillies par les bureaux de statistique et d'autres institutions comptentes, y compris les autorits sectorielles. La rgression linaire est utilise pour fournir des estimations de la population utilisant des installations sanitaires amliores, ainsi que la proportion pratiquant la dfcation  l'air libre. Des rgressions sont galement effectues pour estimer la population utilisant des installations sanitaires amliores relies aux gouts et aux fosses septiques; celles-ci sont contraints de ne pas dpasser les estimations du nombre total d'installations amliores. La proportion de la population partageant des installations sanitaires avec et sans gouts est estime en prenant une moyenne de toutes les donnes disponibles sur le partage provenant d'enqutes et de recensements auprs des mnages. Les services sanitaires de base sont calculs en multipliant la proportion de la population utilisant des installations sanitaires amliores par la proportion d'installations sanitaires amliores qui ne sont pas partages entre deux mnages ou plus. Des estimations distinctes sont faites pour les zones urbaines et rurales, et les estimations nationales sont gnres sous forme de moyennes pondres des deux, en utilisant les donnes dmographiques du rapport le plus rcent de la Division de la population des Nations Unies. L'enqute auprs des mnages ou le recensement le plus rcent disponible pour la plupart des pays a gnralement t ralis il y a deux  six ans. Le Programme conjoint extrapole les rgressions sur deux ans au-del du dernier point de donnes disponible. Au-del de ce point, les estimations restent inchanges jusqu' quatre ans, sauf si la couverture est infrieure  0,5 % ou suprieure  99,5 %, auquel cas la limite est prolonge indfiniment. Pour plus d'informations, consulter https://washdata.org/monitoring/methods/estimation-methods</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Notes au sujet de la CSU</p>\n      </td>\n      <td>\n        <p>L'indicateur ODD au sujet de systme sanitaire (ODD 6.2.1) est une version\nlargie de l'indicateur OMD, intgrant la qualit des installations d'assainissement. Il n'est pas pour la surveillance de la CSU en raison de la faible disponibilit des donnes. Un indicateur conjoint qui identifie la proportion de mnages ayant accs  la fois  l'eau potable et  un systme sanitaire pourrait galement tre envisag.</p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>Indicateur traceur</p>\n      </td>\n      <td>\n        <p>Prvention de maladie cardiovasculaire</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Dfinition de l'indicateur</p>\n      </td>\n      <td>\n        <p>Prvalence normalise selon lge de la tension artrielle normale chez\nles adultes gs de 18 ans ou plus, quel que soit le statut du traitement</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numrateur</p>\n      </td>\n      <td>\n        <p>Nombre d'adultes gs de 18 ans ou plus avec une tension artrielle systolique\n&lt; 140 mm Hg ou tension artrielle diastolique &lt; 90 mm Hg (quel que soit le statut du traitement)</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Dnominateur</p>\n      </td>\n      <td>\n        <p>Nombre d'adultes gs de 18 ans ou plus</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Sources principales de donnes</p>\n      </td>\n      <td>\n        <p>Enqutes bases sur la population et systmes de surveillance</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mthode de mesure</p>\n      </td>\n      <td>\n        <p>Les sources de donnes enregistrant la tension artrielle mesure sont\nutilises (les donnes autodclares sont exclues). Si plusieurs lectures de tension artrielle sont prises par participant, la premire lecture est abandonne et on fait la moyenne des lectures restantes.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mthode d'estimation</p>\n      </td>\n      <td>\n        <p>Pour produire des estimations nationales comparables, les donnes d'observation\nde la prvalence dfinies en termes de seuils alternatifs de tension artrielle systolique et/ou diastolique sont converties en prvalence de l'hypertension artrielle, soit une tension artrielle systolique &gt; 140 mm Hg ou une tension artrielle diastolique &gt; 90 mm Hg,  l'aide d'quations de rgression. Un modle hirarchique baysien est ensuite ajust  ces donnes pour calculer les prvalences spcifiques par ge-sexe-anne-pays, qui tient compte des sources de donnes nationales par rapport aux sources de donnes infranationales, des sources de donnes urbaines par rapport aux rurales, et permet une variation de la prvalence selon l'ge et le sexe. Des estimations normalises selon l'ge sont ensuite produites en appliquant les estimations brutes  la population type de l'OMS. Les dtails sur les mthodes statistiques sont  l'adresse : https://www.thelancet.com/journals/lancet/article/piiS0140-6736(21)01330-1/fulltext</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Notes au sujet de la CSU</p>\n      </td>\n      <td>\n        <p>Les estimations de prvalence sont converties en prvalence de tension\nartrielle normale pour tre incorpores dans l'indice de la CSU, de sorte qu'une valeur de 100 % soit la cible optimale. Ceci est calcul comme suit : prvalence de la tension artrielle normale = 1  prvalence de la tension artrielle leve. Les estimations ci-dessus sont faites sparment pour les hommes et les femmes; pour l'indicateur traceur de la CSU, une simple moyenne des valeurs pour les hommes et les femmes est calcule.</p>\n        <p>La tension artrielle normale est la somme du pourcentage de personnes\nqui ne souffrent pas d'hypertension et du pourcentage de personnes dont l'hypertension est contrle par des mdicaments. L'absence d'hypertension est le rsultat d'efforts de prvention via la promotion de l'activit physique et d'une alimentation saine, ainsi que d'autres facteurs. L'hypertension contrle par des mdicaments est le rsultat d'un traitement efficace. Cet indicateur est donc un indicateur indirect de l'efficacit de la promotion de la sant et de l'efficacit des services mdicaux. </p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>Indicateur traceur</p>\n      </td>\n      <td>\n        <p>Gestion du diabte</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Dfinition de l'indicateur</p>\n      </td>\n      <td>\n        <p>Glucose plasmatique moyen  jeun normalis par ge pour les adultes gs\nde 18 ans ou plus</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Sources principales de donnes</p>\n      </td>\n      <td>\n        <p>Enqutes bases sur la population et systmes de surveillance</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mthode de mesure</p>\n      </td>\n      <td>\n        <p>Les niveaux de glucose plasmatique  jeun sont dtermins en prlevant\nun chantillon de sang de participants qui ont jen pendant au moins 8 heures. D'autres biomarqueurs apparents, tels que l'hmoglobine A1c (HbA1c), ont t utiliss pour aider  calculer les estimations (voir ci-dessous).</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mthode d'estimation</p>\n      </td>\n      <td>\n        <p>Pour produire des estimations nationales comparables, les observations\nde donnes bases sur le glucose plasmatique  jeun moyen, le test de tolrance au glucose oral (OGTT), l'HbA1c ou leurs combinaisons sont toutes converties en glucose plasmatique  jeun moyen. Un modle hirarchique baysien est ensuite ajust  ces donnes pour calculer les prvalences spcifiques par ge-sexe-anne-pays, qui tient compte des sources de donnes nationales par rapport aux sources de donnes infranationales, des sources de donnes urbaines par rapport aux rurales, et permet une variation de la prvalence selon l'ge et le sexe. Des estimations normalises selon l'ge sont ensuite produites en appliquant les estimations brutes  la population type de l'OMS. Les dtails mthodologiques peuvent tre trouvs dans le Rapport mondial sur le diabte  l'adresse : <a href=\"http://apps.who.int/iris/bitstream/handle/10665/254648/9789242565256-fre.pdf?sequence=1\">http://apps.who.int/iris/bitstream/handle/10665/254648/9789242565256-fre.pdf?sequence=1</a></p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Notes au sujet de la CSU</p>\n      </td>\n      <td>\n        <p>Le glucose plasmatique  jeun d'un individu peut tre faible en raison\nd'un traitement efficace avec des mdicaments hypoglycmiants, ou parce que l'individu n'est pas diabtique en raison d'activits de promotion de la sant ou d'autres facteurs tels que la gntique. Le glucose plasmatique  jeun moyen est donc un indicateur  la fois de la promotion efficace d'une alimentation et de comportements sains et d'un traitement efficace du diabte.</p>\n        <p>Les estimations ci-dessus sont produites sparment pour les hommes et\nles femmes; pour l'indicateur traceur de la CSU, une simple moyenne des valeurs pour les hommes et les femmes est calcule.</p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>Indicateur traceur</p>\n      </td>\n      <td>\n        <p>Contrle du tabac</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Dfinition de l'indicateur</p>\n      </td>\n      <td>\n        <p>Prvalence normalise selon lge des adultes d'au moins 15 ans n'ayant\npas fum de tabac au cours des 30 derniers jours </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numrateur</p>\n      </td>\n      <td>\n        <p>Nombre d'adultes d'au moins 15 ans n'ayant pas fum de tabac au cours\ndes 30 derniers jours</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Dnominateur</p>\n      </td>\n      <td>\n        <p>Nombre d'adultes d'au moins 15 ans</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Sources principales de donnes</p>\n      </td>\n      <td>\n        <p>Enqutes auprs des mnages</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mthode de mesure</p>\n      </td>\n      <td>\n        <p>Les produits du tabac comprennent les cigarettes, les pipes, les cigares,\nles cigarillos, les pipes  eau (narguil, chicha), les bidis, le kretek, les produits du tabac chauffs et toutes les formes de tabac sans fume (oral et nasal). Les produits du tabac excluent les e-cigarettes (qui ne contiennent pas de tabac), les e-cigares, les e-narguils, les JUUL et les e-pipes.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mthode d'estimation</p>\n      </td>\n      <td>\n        <p>Un modle statistique bas sur une mta-rgression binomiale ngative\nbaysienne est utilis pour modliser la prvalence de la consommation actuelle de tabac pour chaque pays, sparment pour les hommes et les femmes. Une description complte de la mthode est disponible dans un article valu par des pairs dans The Lancet, volume 385, n 9972, p966-976 (2015). Une fois que les taux de prvalence par ge et par sexe des enqutes nationales ont t compils dans un ensemble de donnes, le modle a t adapt pour calculer les estimations de tendance de l'anne 2000  2025. Le modle comporte deux composantes principales : (a) ajustement pour les indicateurs manquants et groupes d'ge, et (b) gnrer une estimation des tendances dans le temps ainsi que l'intervalle de confiance  95 % autour de l'estimation. Selon l'intgralit/l'exhaustivit des donnes d'enqute d'un pays en particulier, le modle utilise parfois des donnes d'autres pays pour combler les lacunes en matire d'information. Lorsqu'un pays a ralis moins de deux enqutes nationales reprsentatives de la population au cours d'annes diffrentes, aucune tentative n'est faite pour combler les lacunes dans les donnes et aucune estimation n'est calcule. Pour combler les lacunes dans les donnes, les informations sont  empruntes  aux pays de la mme sous-rgion des Nations Unies. Les lignes de tendance rsultantes sont utilises pour driver des estimations pour des annes individuelles, de sorte qu'un nombre peut tre rapport mme si le pays n'a pas men d'enqute cette anne-l. Afin de rendre les rsultats comparables entre les pays, les taux de prvalence sont normaliss selon l'ge par rapport  la population type de l'OMS. Les estimations pour les pays avec des enqutes irrgulires ou de nombreuses lacunes dans les donnes auront de larges intervalles d'incertitude, et ces rsultats doivent tre interprts avec prudence. </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Notes au sujet de la CSU</p>\n      </td>\n      <td>\n        <p>La prvalence de ne pas fumer de tabac est calcule comme 1 moins la\nprvalence de fumer du tabac. </p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>Indicateur traceur</p>\n      </td>\n      <td>\n        <p>Accs  lhpital</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Indicator definition</p>\n      </td>\n      <td>\n        <p>Lits dhpital par habitant, par rapport  un seuil maximum de 18 pour\n10000 habitants</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numrateur</p>\n      </td>\n      <td>\n        <p>Nombre de lits d'hpital (devrait exclure les lits pour le travail et\npour l'accouchement)</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Dnominateur</p>\n      </td>\n      <td>\n        <p>Population totale </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Sources principales de donnes</p>\n      </td>\n      <td>\n        <p>Systmes administratifs / Systme de dclaration des tablissements de\nsant</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mthode de mesure</p>\n      </td>\n      <td>\n        <p>Les systmes administratifs des pays sont utiliss pour totaliser le\nnombre de lits d'hpitaux, qui est divis par la population totale estime et multipli par 10000. </p>\n        <p>Les bureaux rgionaux de l'OMS et d'autres groupes recueillent des informations\nsur la densit nationale des lits d'hpitaux, y compris les ressources en ligne suivantes :</p>\n        <p>Observatoire rgional de l'OMS EMRO : https://rho.emro.who.int/rhodata/node.main.A36</p>\n        <p>Observatoire rgional de l'OMS AFRO : http://www.aho.afro.who.int/en/data-statistics/hospital-beds-10-000-population</p>\n        <p>Base de donnes de l'OMS EURO European Health for All : https://gateway.euro.who.int/en/datasets/european-health-for-all-database/</p>\n        <p>OCDE: https://data.oecd.org/healtheqt/hospital-beds.htm</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mthode d'estimation</p>\n      </td>\n      <td>\n        <p> partir des donnes disponibles, l'indicateur est calcul par rapport\n une valeur seuil de 18 lits d'hpitaux pour 10000 habitants. Ce seuil est infrieur au minimum observ pour les pays  revenu lev de l'OCDE (depuis l'an 2000) de 20 pour 10000 et tend  correspondre  un taux d'hospitalisation d'environ 5 pour 100 par an. Cet indicateur est conu pour saisir les faibles niveaux de capacit hospitalire; le seuil maximal est utilis parce que des densits de lits d'hpitaux trs leves ne sont pas ncessaires  une utilisation efficace des ressources. L'indicateur est calcul comme suit, en utilisant les donnes nationales sur la densit des lits d'hpitaux (<em>x</em>), ce qui donne des valeurs allant de 0  100 :</p>\n        <ul>\n          <li>Pays avec une densit de lits d'hpital <em>x</em> &lt; 18 pour 10000\nhabitants, par anne, l'indicateur = <em>x</em> /18*100. </li>\n          <li>Pays avec une densit de lits d'hpital <em>x</em> &gt;= 18 pour 10000\nhabitants, par anne, l'indicateur = 100.</li>\n        </ul>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Notes au sujet de la CSU</p>\n      </td>\n      <td>\n        <p>Un autre indicateur pourrait tre le taux d'hospitalisation des patients,\npar rapport  un seuil maximal. Cependant, cet indicateur n'est actuellement pas largement dclar dans toutes les rgions, en particulier dans la rgion africaine. Dans les pays o les lits d'hpitaux par habitant et les taux d'hospitalisation sont disponibles, ils sont fortement corrls.</p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>Indicateur traceur</p>\n      </td>\n      <td>\n        <p>Personnel de sant</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Dfinition de l'indicateur</p>\n      </td>\n      <td>\n        <p>Professionnels de la sant (mdecins, psychiatres et chirurgiens) par\nhabitant, par rapport aux seuils maximaux pour chaque groupe</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numrateur</p>\n      </td>\n      <td>\n        <p>Nombre de mdecins, psychiatres et chirurgiens</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Dnominateur</p>\n      </td>\n      <td>\n        <p>Population totale</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Sources principales de donnes</p>\n      </td>\n      <td>\n        <p>Base de donnes ou registre national du personnel de sant, idalement\nassoci  une valuation rgulire de l'exhaustivit  l'aide des donnes de recensement, des registres des associations professionnelles ou des recensements des tablissements</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mthode de mesure</p>\n      </td>\n      <td>\n        <p>La classification du personnel de sant est base sur des critres d'enseignement\net de formation professionnels, de rglementation des professions de sant et d'activits et de tches professionnelles, c'est--dire un cadre de catgorisation des variables cls de la main-d'uvre en fonction de caractristiques communes. Le cadre de l'OMS s'inspire largement des dernires rvisions des systmes de classification normaliss au niveau international de l'Organisation internationale du travail (Classification internationale type des professions), de l'Organisation des Nations Unies pour l'ducation, la science et la culture (Classification internationale type de l'ducation) et de la Division de la statistique des Nations Unies (Classification internationale type par industrie, de toutes les branches d'activit conomique). Les dtails mthodologiques et les donnes peuvent tre trouvs  l'adresse : <a href=\"http://www.who.int/hrh/statistics/hwfstats/en/\">http://www.who.int/hrh/statistics/hwfstats/en/</a></p>\n        <p>Les donnes proviennent des sources suivantes :</p>\n        <p>Mdecins : <a href=\"http://apps.who.int/gho/data/node.main.HWFGRP_0020?lang=en\">http://apps.who.int/gho/data/node.main.HWFGRP_0020?lang=en</a></p>\n        <p>Psychiatres : <a href=\"https://www.who.int/fr/publications/i/item/WHO-HIS-HGF-17.2\">https://www.who.int/fr/publications/i/item/WHO-HIS-HGF-17.2</a></p>\n        <p>Chirurgiens : http://apps.who.int/gho/data/node.main.HWF9?lang=en (ces\ndonnes ont t compltes par des ditions antrieures de la base de donnes)</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mthode d'estimation</p>\n      </td>\n      <td>\n        <p> l'aide des donnes disponibles, l'indicateur est calcul en rchelonnant\nd'abord, sparment, les ratios de densit du personnel de sant pour chacun des trois groupes (mdecins, psychiatres et chirurgiens) par rapport aux valeurs minimales observes dans les pays de l'OCDE depuis 2000, qui sont les suivantes : mdecins = 0,9 pour 1000, psychiatres = 1 pour 100000 et chirurgiens = 14 pour 100000. Cette remise  l'chelle est effectue de la mme manire que pour l'indicateur de densit de lits d'hpitaux dcrit ci-dessus, ce qui donne des valeurs d'indicateur allant de 0  100 pour chacun des trois groupes. Par exemple, en utilisant les donnes nationales sur les mdecins pour 1000 habitants (<em>x</em>), l'indicateur spcifique au groupe serait calcul comme suit :</p>\n        <ul>\n          <li>Pays avec <em>x</em> &lt; 0,9 pour 1000 habitants, par anne, l'indicateur\nspcifique  ce groupe = <em>x</em> /0.9*100. </li>\n          <li>Pays avec <em>x</em> &gt;= 0,9 pour 1000 habitants, par anne, l'indicateur\nspcifique  ce groupe = 100.</li>\n        </ul>\n        <p>Dans une dernire tape, la moyenne gomtrique des trois valeurs d'indicateur\nspcifique  chaque groupe est calcule pour obtenir l'indicateur final de la densit des effectifs de sant.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Notes au sujet de la CSU</p>\n      </td>\n      <td>\n        <p>La catgorie mdecins serait idalement largie pour inclure tous\nles professionnels de la sant de base, tels que les infirmires et les sages-femmes. Cependant, il n'existe aucune base de donnes internationalement comparable qui utilise des dfinitions cohrentes des principaux professionnels de la sant non mdecins pour permettre des comparaisons prcises entre les pays. </p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p>Indicateur traceur</p>\n      </td>\n      <td>\n        <p>Scurit sanitaire</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Dfinition de l'indicateur</p>\n      </td>\n      <td>\n        <p>Indice de capacit de base du Rglement sanitaire international (RSI),\nqui est le pourcentage moyen dattributs de 13 capacits de base qui ont t atteintes  un moment prcis. </p>\n        <p>Les 13 capacits de base sont : (1) Lgislation nationale, politique\net financement; (2) Coordination et communication du correspondant national ; (3) Surveillance; (4) Rponse; (5) tat de prparation; (6) Communication des risques; (7) Ressources humaines; (8) Laboratoire; (9) Points d'entre; (10) vnements zoonotiques; (11) Scurit alimentaire; (12) vnements chimiques; (13) Urgences radionuclaires.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Numrateur</p>\n      </td>\n      <td>\n        <p>Nombre d'attributs atteints</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Dnominateur</p>\n      </td>\n      <td>\n        <p>Nombre total d'attributs</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Sources principales de donnes</p>\n      </td>\n      <td>\n        <p>Sondage auprs des informateurs cls</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mthode de mesure</p>\n      </td>\n      <td>\n        <p>Les informateurs cls rendent compte de la ralisation d'un ensemble\nd'attributs pour chacune des 13 capacits de base  l'aide d'un instrument standard de l'OMS. Cet instrument est bas sur une auto-valuation et une auto-dclaration par l'tat partie. Le questionnaire a t rvis en 2018 et a t utilis pour les rapports en 2018 et 2019 avec le mme format, diffrent du questionnaire utilis pendant la priode 2010-2017, il y a donc une limite pour la comparaison des scores des rapports entre la priode 2010-2017 avec les rapports  partir de 2018.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Mthode d'estimation</p>\n      </td>\n      <td>\n        <p>Le score de chaque niveau d'indicateur est class en pourcentage de performance\nsur l'chelle de 1  5, p. ex., pour un pays slectionnant le niveau 3 pour l'indicateur 2.1, le niveau de l'indicateur sera exprim comme suit : NIVEAU DE CAPACIT = 3/5*100 = 60%. Le niveau de capacit est exprim comme la moyenne de tous les indicateurs. Si un pays slectionne, p. ex., le niveau 3 pour l'indicateur 2.1 et le niveau 4 pour l'indicateur 2.2, le niveau d'indicateur pour 2.1 sera exprim comme suit : 3/5*100 = 60 %, le niveau d'indicateur pour 2.2 sera exprim comme suit : 4/5*100 = 80 % et le niveau de capacit pour les deux sera exprim comme suit: (60+80)/2 = 70% .</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>Notes au sujet de la CSU</p>\n      </td>\n      <td>\n        <p>Les pays ont commenc  communiquer  l'OMS l'atteinte des capacits\nde base du RSI pour l'anne 2010. Le premier score RSI disponible pour chaque pays est utilis pour toutes les annes 2000-2009.</p>\n      </td>\n    </tr>\n  </tbody>\n</table>","pt":"","ru":"<h1></h1>\n<h2><strong>URL: </strong></h2>\n<p><a href=\"http://www.who.int/healthinfo/universal_health_coverage/en/\">http://www.who.int/healthinfo/universal_health_coverage/en/</a></p>\n<h2><strong>: </strong></h2>\n<p><a href=\"http://www.who.int/healthinfo/universal_health_coverage/report/2017/en/\">http://www.who.int/healthinfo/universal_health_coverage/report/2017/en/</a></p>\n<p><a href=\"http://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X(17)30472-2.pdf\">http://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X(17)30472-2.pdf</a></p>\n<p><a href=\"http://www.who.int/healthinfo/universal_health_coverage/en/\">http://www.who.int/healthinfo/universal_health_coverage/en/</a></p>\n<p>    .:</p>\n<p><a href=\"http://www.who.int/healthinfo/universal_health_coverage/UHC_WHS2016_TechnicalNote_May2016.pdf?ua=1\">http://www.who.int/healthinfo/universal_health_coverage/UHC_WHS2016_TechnicalNote_May2016.pdf?ua=1</a> (  )</p>\n<p><a href=\"http://www.who.int/healthinfo/universal_health_coverage/report/2015/en/\">http://www.who.int/healthinfo/universal_health_coverage/report/2015/en/</a></p>\n<p><a href=\"http://www.who.int/healthinfo/universal_health_coverage/report/2014/en/\">http://www.who.int/healthinfo/universal_health_coverage/report/2014/en/</a></p>\n<p><a href=\"http://collections.plos.org/uhc2014\">http://collections.plos.org/uhc2014</a></p>\n<h1> 1.    ,           3.8.1 . </h1>\n<p>       : <a href=\"mailto:uhc_stats@who.int\">uhc_stats@who.int</a></p>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p> </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>    (15 - 49 ),       ,           </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p></p>\n      </td>\n      <td>\n        <p>          15-49 ,   </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p></p>\n      </td>\n      <td>\n        <p>           15-49 ,    </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>  </p>\n      </td>\n      <td>\n        <p>   </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </td>\n      <td>\n        <p>                   .             (15 - 49 ),                          ,      .      -      (15 - 49 ),      ,       ,    -   (  ),  ,                .  :</p>\n           (     ),         ; </p>\n        <p>      (    ),             ; </p>\n        <p>    (     ),        ,        (   ),      ,   ,     ,          (    ),      . </p>\n        <p>       ,   (), , ,   ,    ,    ( ,     , ,   ),    (),      ,      .</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </td>\n      <td>\n        <p>                  ,    ,      .              ,        .      ,     . </p>\n         <p>  . : <a href=\"http://www.un.org/en/development/desa/population/theme/family-planning/cp_model.shtml\">http://www.un.org/en/development/desa/population/theme/family-planning/cp_model.shtml</a></p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>,   </p>\n      </td>\n      <td></td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>    </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>    15-49 ,       ,         </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p></p>\n      </td>\n      <td>\n        <p>    15-49 ,       ,        </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p></p>\n      </td>\n      <td>\n        <p>     15-49 ,        .</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>  </p>\n      </td>\n      <td>\n        <p>       </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>            ,   ,          .   ,       ,  DHS, MICS, RHS   ,    .     /    ,   ,        .</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>       : <a href=\"http://apps.who.int/gho/data/node.main.ANTENATALCARECOVERAGE4\">http://apps.who.int/gho/data/node.main.ANTENATALCARECOVERAGE4</a></p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>,   </p>\n      </td>\n      <td>\n        <p>              , ,  ,           .       ,  ,     .</p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<p><br></p>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p> </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p> ,      ,   </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p></p>\n      </td>\n      <td>\n        <p>  1 ,      ,   .</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p></p>\n      </td>\n      <td>\n        <p>     1 </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>  </p>\n      </td>\n      <td>\n        <p>      </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>   ,       12  23       ,   ,    .         ,    .</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>           ,    (3)   ,       -,   ,      \"\" .       -             -          .    ,       ,  /        . </p>\n         <p>  . : \n        <a href=\"http://www.who.int/bulletin/volumes/87/7/08-053819/en/\">http://www.who.int/bulletin/volumes/87/7/08-053819/en/</a></p>\n        <p><a href=\"http://www.who.int/immunization/monitoring_surveillance/routine/coverage/en/index4.html\">http://www.who.int/immunization/monitoring_surveillance/routine/coverage/en/index4.html</a></p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>,   </p>\n      </td>\n      <td>\n        <p>      .  ,           ,  ,      .  ,          , -    3      .   ,       , ,   B     B,     ,         . </p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>  (     )</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>     5      (   ,  -       )    ,  ,        .</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p></p>\n      </td>\n      <td>\n        <p>         ,  ,    .</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p></p>\n      </td>\n      <td>\n        <p>        ,  .</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>  </p>\n      </td>\n      <td>\n        <p> </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>   /     ,   - 17-18  2004 ,       ()   ,         .   ,         (DHS)        (MICS),         ,  ,  ,  ,  ,     ,   ,      .  \"\"       . </p>\n         <p>             ,      : <a href=\"http://apps.who.int/gho/data/node.main.38?lang=en\">http://apps.who.int/gho/data/node.main.38?lang=en</a></p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>           .</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>,   </p>\n      </td>\n      <td>\n        <p>               . </p>\n         <p>  ,     ,      ,           ( -),     ,  ,              ,    : <a href=\"https://www.who.int/healthinfo/global_burden_disease/estimates/en/index2.html\">https://www.who.int/healthinfo/global_burden_disease/estimates/en/index2.html</a></p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p> </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>   ,         </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p></p>\n      </td>\n      <td>\n        <p>    ,      </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p></p>\n      </td>\n      <td>\n        <p>        </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>  </p>\n      </td>\n      <td>\n        <p>  ,  ,         ,        (   )</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>      : </p>\n         <p> (1)      ,                  . </p>\n         <p> (2)          . </p>\n         <p> (3)   ,   (    )   ,       .</p>\n        <p>  = (1)/(2) x (3)</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>      -       .         ,        ,           (  ).                   : </p>\n         <p> 1.  =    /    ; </p>\n         <p> 2.  =  /  ; </p>\n         <p> 3.  =   /      . </p>\n         <p>               ,       ,   .</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>,   </p>\n      </td>\n      <td>\n        <p>      ,       : <a href=\"http://www.who.int/tb/country/data/download/en/\">http://www.who.int/tb/country/data/download/en/</a>, and compute the indicator as = c_cdr x c_new_tsr</p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p> </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p> ,   ,       ()</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p></p>\n      </td>\n      <td>\n        <p>   ,      </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p></p>\n      </td>\n      <td>\n        <p>   ,   ,    </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>  </p>\n      </td>\n      <td>\n        <p>  ,   ,  </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>:   ,     ,        .               .          ,         . ,       ,     . </p>\n         <p> :      -      ,          ,   ,    .</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>    ,     2000-2018 ,         2019 .</p>\n         <p>    ,   ,           ,         (Spectrum),          ,  ,       -. </p>\n         <p>      ,   ,     ,  ,            . </p>\n        <p>     : <a href=\"http://aidsinfo.unaids.org/\">http://aidsinfo.org</a></p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>,   </p>\n      </td>\n      <td>\n        <p>         ,    ,   .</p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p> </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>      ,         .</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p></p>\n      </td>\n      <td>\n        <p>      ,       </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p></p>\n      </td>\n      <td>\n        <p>       .</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>  </p>\n      </td>\n      <td>\n        <p>          ()          ,        ,         .    ,    ,  Milliner Global Associates,     ,   ,      .</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>       ,    -.        ,   ,        ,      62 ,       . </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>                                    .          .              2015 :<a href=\"http://www.who.int/malaria/publications/world-malaria-report-2015/report/en/\">http://www.who.int/malaria/publications/world-malaria-report-2015/report/en/</a>.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>,   </p>\n      </td>\n      <td>\n        <p>       40     .             -  . </p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>  </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p> ,      </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p></p>\n      </td>\n      <td>\n        <p>,   ,  :      ,       ;     ;    ;   .</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p></p>\n      </td>\n      <td>\n        <p>  </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>  </p>\n      </td>\n      <td>\n        <p>     </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>   ,    ,     .</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>    /     ,   ,      .                  ,    ,          ,        4 ,    .        ,         .           .: <a href=\"http://www.wssinfo.org/\">http://www.wssinfo.org</a></p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>,   </p>\n      </td>\n      <td>\n        <p>     ( 6.2.1)      ,    .       -    .     ,   ,      ,     .</p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p> - </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>           18+,    </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p></p>\n      </td>\n      <td>\n        <p>    18        <140  . .     <90  . . (   )</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p></p>\n      </td>\n      <td>\n        <p>    18   </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>  </p>\n      </td>\n      <td>\n        <p>    </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>  ,     (   ).         ,   ,    .</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>        ,         /  ,      ,      > = 140  . .     > = 90 . . .    .             , ,   ,       ,              .              .       : <a href=\"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31919-5/fulltext\">http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31919-5/fulltext</a></p>\n        <p>        -  (NCD-RisC)         2015 ,   : </p>\n        <p><a href=\"http://apps.who.int/gho/data/node.main.A875STANDARD?lang=en\">http://apps.who.int/gho/data/node.main.A875STANDARD?lang=en</a></p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>,   </p>\n      </td>\n      <td>\n        <p>            ,    100%   .   :     = 1 -    .        ;            </p>\n         <p>    -    ,   ,   ,     .      ,        ,    . ,  , -    .  ,        ,     .</p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p> </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>             18   </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>  </p>\n      </td>\n      <td>\n        <p>    </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>     ()      ,    8 .   ,    A1c (HbA1c),     (. ).</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>       ,     ,       (OGTT), HbA1c   ,     .             , ,   ,       ,              .              .     : <a href=\"https://www.who.int/diabetes/global-report/en/\">https://www.who.int/diabetes/global-report/en/</a></p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>,   </p>\n      </td>\n      <td>\n        <p>     -      - ,              ,   .  ,            ,     . </p>\n         <p>        ;           .</p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>  </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>       > = 15 ,       30  </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p></p>\n      </td>\n      <td>\n        <p>  15   ,       30 </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p></p>\n      </td>\n      <td>\n        <p>  15   </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>  </p>\n      </td>\n      <td>\n        <p> </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>\" \"  , ,       ,    30 .      .</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>     ()      -,                ,   .        .     :<a href=\"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)60264-1/supplemental\">http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)60264-1/supplemental</a></p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>,   </p>\n      </td>\n      <td>\n        <p>      1   </p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>  </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>          18  10 000 </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p></p>\n      </td>\n      <td>\n        <p>   (      )</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p></p>\n      </td>\n      <td>\n        <p>  </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>  </p>\n      </td>\n      <td>\n        <p>  /    </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>        ,           10 000. </p>\n         <p>           -   ,   -:</p>\n        <p><a href=\"https://rho.emro.who.int/rhodata/node.main.A36\">https://rho.emro.who.int/rhodata/node.main.A36</a></p>\n        <p>   AFRO: <a href=\"http://www.aho.afro.who.int/en/data-statistics/hospital-beds-10-000-population\">http://www.aho.afro.who.int/en/data-statistics/hospital-beds-10-000-population</a></p>\n        <p>    \"  \": <a href=\"https://gateway.euro.who.int/en/datasets%20european-health-for-all-database/\">https://gateway.euro.who.int/en/datasets european-health-for-all-database/</a></p>\n        <p>: <a href=\"https://data.oecd.org/healtheqt/hospital-beds.htm\">https://data.oecd.org/healtheqt/hospital-beds.htm</a></p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>         18    10 000 .             ( 2000 ),  20  10 000, ,  ,     5  100  .          ;   ,             .              (x),     0  100:</p>\n        <p>     x <18  10 000  ,  = </p>\n        <p><em>x</em> /18*100. </p>\n        <p>     x> = 18  10 000  ,  = 100.</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>,   </p>\n      </td>\n      <td>\n        <p>          .           ,    .  ,        ,    ,   .</p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p> </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>   (,   )           </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p></p>\n      </td>\n      <td>\n        <p> ,   </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p></p>\n      </td>\n      <td>\n        <p>  </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>  </p>\n      </td>\n      <td>\n        <p>      ,            ,      .</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>         ,   ,       ,              .                 (   ),      ,    (   )       (       ). </p>\n        <p>       : <a href=\"http://www.who.int/hrh/statistics/hwfstats/en/\">http://www.who.int/hrh/statistics/hwfstats/en/</a></p>\n        <p>    :</p>\n        <p>: <a href=\"http://apps.who.int/gho/data/node.main.HWFGRP_0020?lang=en\">http://apps.who.int/gho/data/node.main.HWFGRP_0020?lang=en</a></p>\n        <p>: <a href=\"https://www.who.int/healthinfo/universal_health_coverage/report/2017/en/\">https://www.who.int/healthinfo/universal_health_coverage/report/2017/en/</a></p>\n        <p>: <a href=\"http://apps.who.int/gho/data/node.main.HWF9?lang=en%20\">http://apps.who.int/gho/data/node.main.HWF9?lang=en</a> </p>\n        <p>(        )</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>  ,                 (,   )         2000 ,    :  = 0,9  1000,  = 1  100000,  = 14  100000.      ,       ,  ,          0  100      . ,       1000   (<em> x </em>),       :</p>\n        <p>  x <0,9  1000  ,   = x / 0,9 * 100 </p>\n        <p>  x> = 0,9  1000  ,   = 100</p>\n        <p>            ,       .</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>,   </p>\n      </td>\n      <td>\n        <p>\"\"       ,     \"  \",     .         ,         ,   ,       . </p>\n         <p>  ,     ,       ,       100000 ,     ,  ,            </p>\n      </td>\n    </tr>\n  </tbody>\n</table>\n<table>\n  <tbody>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p> </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>    -  (),       13  ,        </p>\n         <p>  13   : (1)  ,   ; (2)      ; (3) ; (4) ; (5) ; (6)   ; (7)  ; (8) ; (9)  ; (10)  ; (11)  ; (12)     ; (13)   .</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p></p>\n      </td>\n      <td>\n        <p>  </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p></p>\n      </td>\n      <td>\n        <p>  </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>  </p>\n      </td>\n      <td>\n        <p>  </p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>          13       ,   : <a href=\"http://apps.who.int/iris/bitstream/10665/84933/1/WHO_HSE_GCR_2013.2_eng.pdf\">http://apps.who.int/iris/bitstream/10665/84933/1/WHO_HSE_GCR_2013.2_eng.pdf</a></p>\n        <p>      : </p>\n        <p><a href=\"http://apps.who.int/gho/data/node.main.IHRSPARALL?lang=en\">http://apps.who.int/gho/data/node.main.IHRSPARALL?lang=en</a></p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p> </p>\n      </td>\n      <td>\n        <p>     13  ,      .</p>\n      </td>\n    </tr>\n    <tr>\n      <td>\n        <p>,   </p>\n      </td>\n      <td>\n        <p>           -  ()  2010 .  2000-2009            .</p>\n      </td>\n    </tr>\n  </tbody>\n</table>"}}